Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 25	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 26	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 27	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:28:56 ON 18 DEC 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:29:05 ON 18 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 DEC 2006 HIGHEST RN 915749-75-6
DICTIONARY FILE UPDATES: 15 DEC 2006 HIGHEST RN 915749-75-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10524626a.str





chain nodes :
10 13 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-15 8-16 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 7-15 8-9 8-16
exact bonds :
9-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,O,X,Ak,CN

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
13:CLASS 14:Atom 15:Atom 16:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,O,X,Ak,CN

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:29:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6296 TO ITERATE

31.8% PROCESSED 2000 ITERATIONS 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 121163 TO 130677
PROJECTED ANSWERS: 76 TO 552

L2 5 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:29:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 127092 TO ITERATE

100.0% PROCESSED 127092 ITERATIONS 302 ANSWERS
SEARCH TIME: 00.00.02

L3 302 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'CAPLUS' ENTERED AT 11:29:39 ON 18 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 18 Dec 2006 VOL 145 ISS 26

FILE LAST UPDATED: 17 Dec 2006 (20061217/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 36 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:699841 CAPLUS
DOCUMENT NUMBER: 145:140139
TITLE: Kinase-directed, activity-based probes
INVENTOR(S): Boyce, James P.; Brown, Michael E.; Fitzner, Jeffrey N.; Kowski, Thomas
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006076463	A2	20060720	WO 2006-US1038	20060112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006211074	A1	20060921	US 2006-331413	20060112
PRIORITY APPLN. INFO.:			US 2005-643609P P	20050112

AB Various embodiments of the present invention are directed to kinase-directed, activity-based probes ("KABPs") that tightly bind to, and label, kinases. Each KABP includes a binding group that is recognized and bound by one or more kinases, a reactive group that tightly, and generally irreversibly, binds to the kinase, a tag group that labels the kinase, or that serves a chemical handle for subsequent procedures and processes, and a linker group that links the tag group to one or more of the reactive group and the binding group. Addnl. embodiments of the present invention are directed to methods for identifying kinases within, and isolating kinases from, living cells by use of one or more KABPs. A kinase-directed, activity-based probe comprises a substituted acrylyl moiety having the structure R3-,R2-C=C-CO,-R1 (I; R1 = substituted anilinoquinazoline, competitive kinase inhibitor, candidate therapeutic drug; R2 = H, halo, (substituted)alkyl; R3 = MeO, glycolylhydroxy bisubstituted Ph linked through an amide bond to a 2-[2-(2-aminoethoxy)ethoxy]ethylamine, in turn linked through an amide bond to a fluorophore tag group, N-alkylated 2-[2-(2-aminoethoxy)ethoxy]ethylamine linked through an amide bond to a fluorophore tag group; R1 and R3 may be interchanged). Representative probes include I (R1 = N4-(3-chloro-4-fluorophenyl)-4,6-quinazolinediamine; R2 = H; R3 = glycolylhydroxy bisubstituted Ph linked through an amide

bond to a 2-[2-(2-aminoethoxy)ethoxy]ethylamine, in turn linked through an amide bond to Bodipy-FL) and I (R1 = N4-(3-chloro-4-fluorophenyl)-4,6-quinazolinediamine; R2 = H; R3 = N-Et 2-[2-(2-aminoethoxy)ethoxy]ethylamine linked through an amide bond to Bodipy-FL).

IT 215306-39-1
RL: NUU (Other use, unclassified); USES (Uses)
(small-organic- mol. competitive inhibitor, binding moiety is; kinase-directed, activity-based probes)

RN 215306-39-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:625359 CAPLUS

DOCUMENT NUMBER: 145:240941

TITLE: Identification of thieno[3,2-b]pyrroles as allosteric inhibitors of hepatitis C virus NS5B polymerase

AUTHOR(S): Ontoria, Jesus M.; Martin Hernando, Jose I.; Malancona, Savina; Attenni, Barbara; Stansfield, Ian; Conte, Immacolata; Ercolani, Caterina; Habermann, Joerg; Ponzi, Simona; Di Filippo, Marcello; Koch, Uwe; Rowley, Michael; Narjes, Frank

CORPORATE SOURCE: Department of Medicinal Chemistry, IRBM-MRL Rome, Pomezia (Rome), 00040, Italy

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(15), 4026-4030
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Thieno[3,2-b]pyrroles are a novel class of allosteric inhibitors of HCV NS5B RNA-dependent RNA polymerase which show potent affinity for the NS5B enzyme. Introduction of a polar substituent in the position N1 led to a compound that efficiently blocks subgenomic HCV RNA replication in HUH-7 cells with an EC50 of 2.9 μM.

IT 905947-27-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(thienopyrroles as allosteric inhibitors of hepatitis C virus NS5B polymerase)

RN 905947-27-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-6-carboxylic acid, 3-cyclohexyl-2-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1324669 CAPLUS
DOCUMENT NUMBER: 144:171145
TITLE: Synthesis of pyridino[3',2':4,5]pyrrolo[3,2-g]pyrrolo[3,4-e]indolizine-1,3-dione and pyrrolo[3,2-c]pyrazole skeletons
AUTHOR(S): Anizon, Fabrice; Pfeiffer, Bruno; Prudhomme, Michelle
CORPORATE SOURCE: Laboratoire SEESIB, UMR 6504 du CNRS, Universite Blaise Pascal, Aubiere, 63177, Fr.
SOURCE: Tetrahedron Letters (2006), 47(4), 433-436
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A 3-step synthesis of an isogranulatimide analog, in which the imidazole moiety is replaced by a pyrrole unit and the indole heterocycle is replaced by a 7-azaindole moiety is described. Moreover, a novel synthetic pathway to the pyrrolo[3,2-c]pyrazole skeleton is reported.
IT 681180-48-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridinopyrrolopyrroloindolizinedione and pyrrolopyrazole skeletons)
RN 681180-48-3 CAPLUS
CN 2,5-Pyrrolidinedione, 3-[2-(1H-pyrrol-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1103779 CAPLUS
DOCUMENT NUMBER: 143:387011
TITLE: Preparation of azaindoles as inhibitors of JAK and other protein kinases
INVENTOR(S): Salituro, Francesco; Farmer, Luc; Bethiel, Randy; Harrington, Edmund; Green, Jeremy; Court, John; Come, Jon; Lauffer, David; Aronov, Alex; Binch, Hayley; Boyall, Dean; Charrier, Jean-Damien; Everitt, Simon; Fraysse, Damien; Mortimore, Michael; Pierard, Francoise; Robinson, Daniel
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA; et al.
SOURCE: PCT Int. Appl., 432 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095400	A1	20051013	WO 2005-US10846	20050330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005228904	A1	20051013	AU 2005-228904	20050330
CA 2560454	A1	20051013	CA 2005-2560454	20050330
EP 1730146	A1	20061213	EP 2005-756052	20050330
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
NO 2006004852	A	20061024	NO 2006-4852	20061024
PRIORITY APPLN. INFO.:			US 2004-557503P P	20040330
			US 2004-625599P P	20041105
			WO 2005-US10846 W	20050330

OTHER SOURCE(S): MARPAT 143:387011

GI



I



II

AB The title compds. I [R1 = TR', Si(R')3; R2-R4 = halo, CN, NO2, etc.; X1-X3 = N, CH (wherein the hydrogen atom of CH is optionally replaced by R5); x = 1-4; R5 = halo, CN, NO2, etc.; T = a bond, alkylidene, etc.; R' = H, alkyl, (hetero)cyclyl, etc.; with provisos] which are inhibitors of protein kinases, were prepared E.g., a multi-step synthesis of II, starting with 7-azaindole, was given. The compds. I were tested against JAK2, JAK3, ROCK and Aurora kinases (data given). The invention also provides pharmaceutical compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders.

IT 663884-05-7P 664990-53-8P 866542-79-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azaindoles as inhibitors of JAK and other protein kinases)

RN 663884-05-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-(4-morpholinyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-53-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2,3-diphenyl- (9CI) (CA INDEX NAME)



RN 866542-79-2 CAPLUS
CN Benzenamine, 4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:823557 CAPLUS
DOCUMENT NUMBER: 143:235399
TITLE: Compositions and methods for treating contracture
INVENTOR(S): Avelar, Rui; Liggins, Richard T.; Toleikis, Philip M.; Loss, Troy A. E.; Gravett, David M.; Maiti, Arpita
PATENT ASSIGNEE(S): Angiotech International A. G., Switz.
SOURCE: PCT Int. Appl., 234 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074913	A2	20050818	WO 2005-US3800	20050131
WO 2005074913	A3	20060119		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005210668	A1	20050818	AU 2005-210668	20050131

CA 2536096	A1	20050818	CA 2005-2536096	20050131
US 2005186261	A1	20050825	US 2005-48628	20050131
EP 1708694	A2	20061011	EP 2005-722794	20050131

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

PRIORITY APPLN. INFO.: US 2004-540660P P 20040130
WO 2005-US3800 W 20050131

AB A method for treating contracture is provided that includes administering to a patient in need thereof a composition that includes a therapeutic agent effective in treating contracture. Compns., devices, and kits for use in treating contracture are also described. A micellar carrier comprised of methoxy-PEG-polylactide diblock copolymer and containing paclitaxel was prepared

IT 215306-39-1, RWJ-68354
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for treating contracture)

RN 215306-39-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2005:380689 CAPLUS
DOCUMENT NUMBER:	143:78104
TITLE:	The Aminopalladation-Reductive Elimination Process as a Tool for the Solution-Phase Synthesis of 2,3-Disubstituted Azaindole Libraries
AUTHOR(S):	Cacchi, Sandro; Fabrizi, Giancarlo; Parisi, Luca M.
CORPORATE SOURCE:	Dipartimento di Studi di Chimica e Tecnologia delle Sostanze Biologicamente Attive, Universita degli Studi La Sapienza, Rome, 00185, Italy
SOURCE:	Journal of Combinatorial Chemistry (2005), 7(4), 510-512 CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER:	American Chemical Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 143:78104

GI



I



II

AB 2,3-Disubstituted 4-azaindole and 7-azaindole libraries were prepared by reaction of alkynes, e.g. I, containing neutral and electron-poor substituents with a variety of electron-rich, electron-poor, and almost neutral aryl

iodides, bromides, and triflates. E.g., reaction of I with RX (RX = 4-EtO2CC6H4I, 4-FC6H4I, etc.) gave 7-azaindoles II. The procedure involves the aminopalladation-reductive elimination of readily available acyclic precursors and allows for the introduction of diversities at the C-2 or the C-3 positions of the free N-H azaindole system, usually in good to excellent yields. The exptl. procedure is simple, and the reaction tolerates many important functional groups both in the alkyne component and in the aryl/heteroaryl halide or vinyl triflate.

IT 855527-37-6P 855527-38-7P 855527-39-8P
855527-40-1P 855527-41-2P 855527-42-3P
855527-43-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(aminopalladation-reductive elimination process as a tool for the solution-phase synthesis of 2,3-disubstituted azaindole libraries from (phenylethynyl)(trifluoroacetamido)pyridines and aryl iodides, bromides, and triflates)

RN 855527-37-6 CAPLUS
CN Benzoic acid, 4-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 855527-38-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-(4-methoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 855527-39-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-(4-fluorophenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 855527-40-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[3,5-bis(trifluoromethyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 855527-41-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-(2-methyl-5-nitrophenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 855527-42-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[1,1'-biphenyl]-4-yl-2-phenyl- (9CI) (CA INDEX NAME)



RN 855527-43-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-phenyl-3-(3,3,5,5-tetramethyl-1-cyclohexen-1-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:908905 CAPLUS
DOCUMENT NUMBER: 142:68509
TITLE: A 3D Similarity Method for Scaffold Hopping from Known Drugs or Natural Ligands to New Chemotypes
AUTHOR(S): Jenkins, Jeremy L.; Glick, Meir; Davies, John W.
CORPORATE SOURCE: Lead Discovery Center, Novartis Institutes for BioMedical Research Inc., Cambridge, MA, 02139, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(25),

6144-6159
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A primary goal of 3D similarity searching is to find compds. with similar bioactivity to a reference ligand but with different chemotypes, i.e., "scaffold hopping". However, an adequate description of chemical structures in 3D conformational space is difficult due to the high-dimensionality of the problem. The authors present an automated method that simplifies flexible 3D chemical descriptions in which clustering techniques traditionally used in data mining are exploited to create "fuzzy" mol. representations called FEPOPS (feature point pharmacophores). The representations can be used for flexible 3D similarity searching given one or more active compds. without a priori knowledge of bioactive conformations or pharmacophores. The authors demonstrate that similarity searching with FEPOPS significantly enriches for actives taken from inhouse high-throughput screening datasets and from MDDR activity classes COX-2, 5-HT3A, and HIV-RT, while also scaffold or ring-system hopping to new chemical frameworks. Further, inhibitors of target proteins (dopamine 2 and retinoic acid receptor) are recalled by FEPOPS by scaffold hopping from their associated endogenous ligands (dopamine and retinoic acid). Importantly, the method excels in comparison to commonly used 2D similarity methods (DAYLIGHT, MACCS, Pipeline Pilot fingerprints) and a com. 3D method (Pharmacophore Distance Triplets) at finding novel scaffold classes given a single query mol.

IT 208104-46-5
RL: PAC (Pharmacological activity); BIOL (Biological study)
(3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes)

RN 208104-46-5 CAPLUS
CN Methanesulfonamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:701815 CAPLUS
DOCUMENT NUMBER: 141:185104
TITLE: Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
INVENTOR(S): Rudolph, Amy E.; Rocha, Ricardo; Carretero, Oscar
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 107 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167197	A1	20040826	US 2004-788220	20040226
WO 2004075852	A2	20040910	WO 2004-US5609	20040226
WO 2004075852	A3	20050728		
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004075857	A2	20040910	WO 2004-US5799	20040226
WO 2004075857	A3	20050818		
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005203072	A1	20050915	US 2004-787721	20040226
PRIORITY APPLN. INFO.:			US 2003-450529P P	20030226

AB This invention is directed generally to a method for treating a pathol. condition (particularly a cardiovascular condition (e.g., hypertension or heart failure) or a condition associated with a cardiovascular condition) using a p38-kinase inhibitor (e.g., a p38-kinase-inhibiting substituted pyrazole), and specifically a combination comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor (or "ACE inhibitor") for treating a cardiovascular condition. This invention also is directed generally to combinations comprising a p38-kinase inhibitor, and specifically to combinations comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor. This invention is further directed generally to pharmaceutical compns. comprising a p38-kinase inhibitor, and more specifically to compns. comprising the above-described combinations.

IT 215306-39-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

RN 215306-39-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:329923 CAPLUS
DOCUMENT NUMBER: 140:357342
TITLE: Preparation of pyrrolo[3,4-c]carbazoles and pyrido[2,3-b]pyrrolo[3,4-e]indoles as antitumor agents for treating leukemia
INVENTOR(S): Prudhomme, Michelle; Hugon, Bernadette; Anizon, Fabrice; Hickman, John; Pierre, Alain; Golsteyn, Roy; Renard, Pierre; Pfeiffer, Bruno
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
SOURCE: Fr. Demande, 71 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2845995	A1	20040423	FR 2002-12846	20021016
CA 2502515	A1	20040429	CA 2003-2502515	20031014
WO 2004035582	A1	20040429	WO 2003-FR3021	20031014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003285397	A1	20040504	AU 2003-285397	20031014
EP 1554277	A1	20050720	EP 2003-778389	20031014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015490	A	20050823	BR 2003-15490	20031014
CN 1705667	A	20051207	CN 2003-80101577	20031014
JP 2006507269	T	20060302	JP 2004-544379	20031014
NO 2005002338	A	20050512	NO 2005-2338	20050512
PRIORITY APPLN. INFO.:			FR 2002-12846 A	20021016
			WO 2003-FR3021 W	20031014

OTHER SOURCE(S): MARPAT 140:357342
GI



I



II



III

AB Title compds. I [wherein A = (un)saturated 6-membered ring; Z = U-V; U = a simple bond or (un)substituted alkylene; V = H, halo, CN, NO2, azido, aryl, aryl/alkyl, OH and derivs., aryloxy, formyl, CO2H and derivs., aminocarbonyl, NH2 and derivs., etc.; CWC = Ph, pyridinyl; B = 5-membered heterocyclyl rings, i.e., pyrrole, imidazole; X1, X2 = independently H, OH and derivs., alkyl/thio; Y1, Y2 = independently H, or X1CY1, X2CY2 = independently thio/carbonyl; R1 = H, (un)substituted alkyl; Q = O, NR2; R2 = aryl, cyclo/cycloalkyl/aryl/alkyl, OH and derivs., NH2 and derivs., CHO and derivs., (un)substituted alkylene, etc.; with provisos; their enantiomers, diastereomers, their salts of addition with a pharmaceutically acceptable acid or base] were prepared as antitumor agents. For example, reacting bromide II (preparation given) with imidazole in the presence of EtMgBr in THF, followed by BOC-protection and ring closure by irradiation with a halogen lamp in MeCN gave the imidazo deriv III (m.p. = 270°). I dispayed a good cytotoxicity against L1210 leukemia murine cell lines in vitro (no data).

IT 681180-48-3P, 3-[2-(1H-Pyrrol-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-2,5-pyrrolidinedione
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrrolo[3,4-c]carbazoles and pyrido[2,3-b]pyrrolo[3,4-e]indoles as antitumor agents for treating leukemia)

RN 681180-48-3 CAPLUS

CN 2,5-Pyrrolidinedione, 3-[2-(1H-pyrrol-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:182368 CAPLUS
DOCUMENT NUMBER: 140:229401
TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands
INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph
PATENT ASSIGNEE(S): Gpc Biotech Inc., USA; Gpc Biotech AG
SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004043388	A1	20040304	US 2002-234985		20020903
US 7135550	B2	20061114			
US 2003165873	A1	20030904	US 2002-91177		20020304
US 2004266854	A1	20041230	US 2004-820453		20040407
PRIORITY APPLN. INFO.:			US 2001-272932P	P	20010302
			US 2001-278233P	P	20010323
			US 2001-329437P	P	20011015
			US 2002-91177	A2	20020304
			US 2001-336962P	P	20011203
			WO 2002-US6677	A2	20020304
			US 2002-234985	A2	20020903
			WO 2002-US33052	A2	20021015
			US 2003-460921P	P	20030407
			US 2003-531872P	P	20031223

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene gycol moiety to dexamethasone, is described.

IT 215306-39-1D, conjugates
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 215306-39-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:162688 CAPLUS
DOCUMENT NUMBER: 140:217628
TITLE: Preparation of substituted pyrrolopyridines as Itk kinase inhibitors
INVENTOR(S): Aadal Nielsen, Peter; Brimert, Thomas; Kristoffersson, Anna; Linnanen, Tero; Sjoe, Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016610	A1	20040226	WO 2003-SE1275	20030813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003253532	A1	20040303	AU 2003-253532	20030813
EP 1539758	A1	20050615	EP 2003-788212	20030813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006500363	T	20060105	JP 2004-529000	20030813
US 2005215582	A1	20050929	US 2005-524361	20050210
PRIORITY APPLN. INFO.:			SE 2002-2463 A	20020814
			WO 2003-SE1275 W	20030813

OTHER SOURCE(S): MARPAT 140:217628
GI



I



II

AB The title compds. [I; R1 = (un)substituted Ph or 5-6 membered aromatic heterocyclyl containing 1-3 heteroatoms selected from O, S and N; R2 =

(un)substituted (un)saturated 3-7 membered ring optionally including 1 or 2 heteroatoms selected from O, N and SOn (n = 0-2); R3 = H, halo, alkyl, alkoxy, CN] and their salts, useful in the treatment or prophylaxis of human diseases or conditions in which inhibition of Itk kinase activity is beneficial such as asthma and allergic rhinitis, were prepared E.g., a 3-step synthesis of II, starting from 5-chloro-3-iodopyridin-2-amine and 2-methyl-4-trimethylsilyl-1-buten-3-yne, was given. The exemplified compds. I showed IC50 of < 25 μM against Itk kinase. The pharmaceutical composition comprising the compound I is claimed.

IT 664361-84-6P 664361-85-7P 664361-89-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted pyrrolopyridines as Itk kinase inhibitors)

RN 664361-84-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[2-[4-[3-(dimethylamino)propoxy]phenyl]-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 664361-85-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[2-(2-furanyl)-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 664361-89-1 CAPLUS
CN 1-Propanamine, 3-[4-[5-chloro-3-(4-piperidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 664361-81-3P 664361-82-4P 664361-83-5P
664361-86-8P 664361-87-9P 664361-88-0P
664361-90-4P 664361-91-5P 664361-92-6P
664361-93-7P 664361-94-8P 664361-95-9P
664361-96-0P 664361-97-1P 664361-98-2P
664361-99-3P 664362-00-9P 664362-01-0P
664362-02-1P 664362-03-2P 664362-04-3P
664362-05-4P 664362-06-5P 664362-07-6P
664362-08-7P 664362-09-8P 664362-22-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyrrolopyridines as Itk kinase inhibitors)

RN 664361-81-3 CAPLUS
CN 1-Propanamine, 3-[4-(5-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-2-yl)phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664361-82-4 CAPLUS
CN 1-Propanamine, 3-[4-[5-chloro-3-(1-cyclohexen-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664361-83-5 CAPLUS
CN 1-Propanamine, 3-[4-[5-chloro-3-(1-cyclohexen-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-N,N-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664361-82-4

CMF C24 H28 Cl N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664361-86-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[2-(2-furanyl)-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 664361-87-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-3-(4-piperidinyl)-2-(1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)







RN 664361-88-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-chloro-2-[4-[3-(dimethylamino)propoxy]phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 664361-90-4 CAPLUS
CN Piperidine, 4-[5-chloro-2-[4-[3-(dimethylamino)propoxy]phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 664361-91-5 CAPLUS
CN 1-Piperidinecarboxaldehyde, 4-[5-chloro-2-[4-[3-(dimethylamino)propoxy]phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 664361-92-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-chloro-2-[4-[3-(dimethylamino)propoxy]phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 664361-93-7 CAPLUS
CN 1-Piperidinecarboxamide, 3-[2-[4-[3-(dimethylamino)propoxy]phenyl]-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664361-94-8 CAPLUS
CN 1-Piperidinecarboxamide, 3-[2-[4-[3-(dimethylamino)propoxy]phenyl]-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 664361-95-9 CAPLUS
CN Piperidine, 3-[2-[4-[3-(dimethylamino)propoxy]phenyl]-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 664361-96-0 CAPLUS
CN Piperidine, 3-[2-[4-[3-(dimethylamino)propoxy]phenyl]-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 664361-97-1 CAPLUS
CN Piperidine, 1-acetyl-3-[2-[4-[3-(dimethylamino)propoxy]phenyl]-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 664361-98-2 CAPLUS
CN 1-Piperidinecarbothioamide, 3-[2-[4-[3-(dimethylamino)propoxy]phenyl]-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 664361-99-3 CAPLUS
CN Piperidine, 1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]sulfonyl]-3-[2-[4-[3-(dimethylamino)propoxy]phenyl]-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 664362-00-9 CAPLUS
CN 2,5-Pyrrolidinedione, 3-[3-[2-[4-[3-(dimethylamino)propoxy]phenyl]-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 664362-01-0 CAPLUS
CN Piperidine, 3-[2-[4-[3-(dimethylamino)propoxy]phenyl]-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 664362-02-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2-(4-methoxyphenyl)-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 664362-03-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2-(4-methoxyphenyl)-3-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664362-02-1
CMF C18 H19 Br N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664362-04-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2-(4-methoxyphenyl)-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 664362-05-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-bromo-2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 664362-06-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-bromo-2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-, 1,1-dimethylethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664362-05-4
CMF C23 H27 Br N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664362-07-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2-(4-methoxyphenyl)-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 664362-08-7 CAPLUS
CN Piperazine, 1-[5-bromo-2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 664362-09-8 CAPLUS
CN 1-Piperazinecarboxaldehyde, 4-[5-bromo-2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 664362-22-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-(4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)



IT 664362-18-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted pyrrolopyridines as Itk kinase inhibitors)
RN 664362-18-9 CAPLUS
CN 1-Propanamine, N,N-dimethyl-3-[4-[5-methyl-3-(3-piperidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:162687 CAPLUS
DOCUMENT NUMBER: 140:217627
TITLE: Preparation of substituted pyrrolopyridines as Itk kinase inhibitors
INVENTOR(S): Aadal Nielsen, Peter; Brimert, Thomas; Kristoffersson, Anna; Linnanen, Tero; Sjoe, Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016609	A1	20040226	WO 2003-SE1272	20030813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003248588	A1	20040303	AU 2003-248588	20030813
EP 1539757	A1	20050615	EP 2003-788209	20030813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006500362	T	20060105	JP 2004-528997	20030813
US 2005261331	A1	20051124	US 2005-524626	20050210
PRIORITY APPLN. INFO.:			SE 2002-2463	A 20020814
			WO 2003-SE1272	W 20030813

OTHER SOURCE(S): MARPAT 140:217627
GI



I

AB The title compds. [I; R1 = (un)substituted Ph, 5-6 membered aromatic heterocyclyl containing 1-3 heteroatoms selected from O, S and N; R2 = (un)substituted Ph, 5-6 membered aromatic heterocyclyl containing 1-3 heteroatoms selected from O, S and N; R3 = H, halo, alkyl, alkoxy, CN] and their salts, useful for treating or reducing the risk of a human disease or condition in which inhibition of Itk kinase activity is beneficial (such as asthma and allergic rhinitis), were prepared Thus, reacting 2-(4-methoxyphenyl)-1-phenylethanone with 5-bromo-2-hydrazinopyridine at 230° afforded 58% 5-bromo-3-(4-methoxyphenyl)-2-phenyl-1H-pyrrolo[2,3-b]pyridine. The exemplified compds. I showed IC50 of < 25 μM against Itk kinase. The pharmaceutical composition comprising the compound I is claimed.

IT 664991-25-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted pyrrolopyridines as Itk kinase inhibitors)

RN 664991-25-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-2-(6-chloro-3-pyridinyl)-3-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)



IT 663884-05-7P 663884-06-8P 663884-07-9P
664990-45-8P 664990-46-9P 664990-47-0P
664990-48-1P 664990-50-5P 664990-51-6P
664990-53-8P 664990-54-9P 664990-55-0P
664990-56-1P 664990-57-2P 664990-58-3P
664990-59-4P 664990-60-7P 664990-61-8P
664990-62-9P 664990-63-0P 664990-64-1P
664990-65-2P 664990-66-3P 664990-67-4P
664990-68-5P 664990-70-9P 664990-71-0P
664990-72-1P 664990-73-2P 664990-74-3P
664990-75-4P 664990-76-5P 664990-77-6P
664990-78-7P 664990-79-8P 664990-80-1P
664990-81-2P 664990-82-3P 664990-83-4P
664990-84-5P 664990-85-6P 664990-86-7P
664990-87-8P 664990-88-9P 664990-89-0P
664990-90-3P 664990-91-4P 664990-92-5P
664990-93-6P 664990-94-7P 664990-95-8P
664990-96-9P 664990-97-0P 664990-98-1P
664990-99-2P 664991-00-8P 664991-01-9P
664991-02-0P 664991-03-1P 664991-04-2P
664991-05-3P 664991-06-4P 664991-07-5P
664991-08-6P 664991-09-7P 664991-10-0P
664991-11-1P 664991-12-2P 664991-13-3P
664991-14-4P 664991-15-5P 664991-16-6P
664991-17-7P 664991-18-8P 664991-19-9P
664991-20-2P 664991-21-3P 664991-22-4P
664991-23-5P 664991-24-6P 664991-26-8P
664991-27-9P 664991-28-0P 664991-29-1P
664991-30-4P 664991-31-5P 664991-32-6P
664991-33-7P 664991-34-8P 664991-35-9P
664991-36-0P 664991-37-1P 664991-38-2P
664991-39-3P 664991-40-6P 664991-41-7P
664991-42-8P 664991-43-9P 664991-44-0P
664991-45-1P 664991-46-2P 664991-47-3P
664991-48-4P 664991-49-5P 664991-50-8P
664991-51-9P 664991-52-0P 664991-53-1P
664991-54-2P 664991-91-7P 664991-92-8P
664991-93-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyrrolopyridines as Itk kinase inhibitors)

RN 663884-05-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-(4-morpholinyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 663884-06-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 663884-07-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 663884-06-8
CMF C25 H24 Br N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-45-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-(4-methoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-46-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-(3-methoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-47-0 CAPLUS
CN Benzonitrile, 4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 664990-48-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2-(2-furanyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 664990-50-5 CAPLUS
CN 1-Propanamine, 3-[4-[5-bromo-2-(2-furanyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664990-51-6 CAPLUS
CN 1-Propanamine, 3-[4-[5-bromo-2-(2-furanyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]phenoxy]-N,N-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-50-5

CMF C22 H22 Br N3 O2







CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-53-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2,3-diphenyl- (9CI) (CA INDEX NAME)



RN 664990-54-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2-(4-bromophenyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 664990-55-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 664990-56-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-[4-[3-(dimethylamino)propoxy]phenyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)







RN 664990-57-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-[4-[3-(dimethylamino)propoxy]phenyl]-2-(2-furanyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-56-1
CMF C23 H22 N4 O2







CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-58-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-phenyl-2-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 664990-59-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-(2-furanyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-60-7 CAPLUS
CN Acetamide, N-[[5-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-furanyl]methyl]- (9CI) (CA INDEX NAME)



RN 664990-61-8 CAPLUS
CN 2-Furanmethanamine, 5-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 664990-62-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2,3-di-2-furanyl- (9CI) (CA INDEX NAME)



RN 664990-63-0 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 1-(5-bromo-3-phenyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 664990-64-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-phenyl-2-(1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)



RN 664990-65-2 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2-(2-oxazolyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 664990-66-3 CAPLUS
CN Phenol, 3-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 664990-67-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-(4-methoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-68-5 CAPLUS
CN 2-Propanol, 1-[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenoxy]-3-[[2-(1-pyrrolidinyl)ethyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 664990-70-9 CAPLUS
CN 1-Pyrrolidineethanol, α-[[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenoxy]methyl]-3-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-69-6
CMF C26 H26 Br N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-71-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-72-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-71-0
CMF C26 H26 Br N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-73-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2-phenyl-3-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 664990-74-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2-phenyl-3-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-73-2
CMF C25 H24 Br N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-75-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-76-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-75-4
CMF C25 H24 Br N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-77-6 CAPLUS
CN 1-Propanamine, 3-[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664990-78-7 CAPLUS
CN 1-Propanamine, 3-[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenoxy]-N,N-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-77-6
CMF C24 H24 Br N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-79-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-80-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-81-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-80-1
CMF C26 H26 Br N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-82-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-[4-[3-(dimethylamino)propoxy]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-83-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-[4-[3-(dimethylamino)propoxy]phenyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-82-3
CMF C25 H24 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-84-5 CAPLUS
CN 2-Oxazolidinone, 5-[[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 664990-85-6 CAPLUS
CN 2-Oxazolidinone, 5-[[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenoxy]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-84-5
CMF C23 H18 Br N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-86-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-[4-[3-(dimethylamino)propoxy]phenyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 664990-87-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-[4-[3-(dimethylamino)propoxy]phenyl]-2-(4-methoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-86-7
CMF C26 H26 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-88-9 CAPLUS
CN 1-Propanamine, 3-[4-[5-bromo-2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664990-89-0 CAPLUS
CN 1-Propanamine, 3-[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 664990-90-3 CAPLUS
CN 1-Propanamine, 3-[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-89-0
CMF C22 H20 Br N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-91-4 CAPLUS
CN Benzenemethanamine, 4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-
(9CI) (CA INDEX NAME)



RN 664990-92-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-(4,5-dihydro-1H-imidazol-2-
yl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-93-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-(4,5-dihydro-1H-imidazol-2-
yl)phenyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-92-5
CMF C22 H17 Br N4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-94-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-(4,5-dihydro-4,4-dimethyl-1H-imidazol-2-yl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 664990-95-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-(4,5-dihydro-4,4-dimethyl-1H-imidazol-2-yl)phenyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-94-7
CMF C24 H21 Br N4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-96-9 CAPLUS
CN Benzamide, N-(2-aminoethyl)-4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 664990-97-0 CAPLUS
CN Benzamide, N-(2-aminoethyl)-4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-96-9
CMF C22 H19 Br N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664990-98-1 CAPLUS
CN 1,2-Propanediol, 3,3'-[[[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]methyl]imino]bis- (9CI) (CA INDEX NAME)



RN 664990-99-2 CAPLUS
CN 1,2-Propanediol, 3,3'-[[[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]methyl]imino]bis-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664990-98-1
CMF C26 H28 Br N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-00-8 CAPLUS
CN Benzoic acid, 4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 664991-01-9 CAPLUS
CN L-Glutamine, N-[[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 664991-02-0 CAPLUS
CN L-Glutamine, N-[[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-01-9
CMF C25 H23 Br N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-03-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-(4-hydroxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 664991-04-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-[4-(aminomethyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 664991-05-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-[4-(aminomethyl)phenyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-04-2
CMF C21 H16 N4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-06-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-[4-(4-morpholinyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 664991-07-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 3-(4-hydroxyphenyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 664991-08-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-2-phenyl-3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 664991-09-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 2-(4-methoxyphenyl)-3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 664991-10-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-(2,5-dimethyl-1H-pyrrol-1-yl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 664991-11-1 CAPLUS
CN 1-Propanamine, N,N-dimethyl-3-[4-[5-methyl-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]- (9CI) (CA INDEX NAME)



RN 664991-12-2 CAPLUS
CN 1-Propanamine, 3-[4-[5-fluoro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664991-13-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile, 2-[4-[3-(dimethylamino)propoxy]phenyl]-4-methyl-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 664991-14-4 CAPLUS
CN Piperazine, 1-[[4-[5-chloro-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 664991-15-5 CAPLUS
CN Piperazine, 1-[[4-[5-chloro-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-pyrrol-2-yl]carbonyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-14-4
CMF C21 H19 Cl N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-16-6 CAPLUS
CN Piperazine, 1-[[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 664991-17-7 CAPLUS
CN Piperazine, 1-[[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-pyrrol-2-yl]carbonyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-16-6
CMF C20 H18 Cl N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-18-8 CAPLUS
CN 1-Propanamine, 3-[4-[4,5-dichloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664991-19-9 CAPLUS
CN 1-Propanamine, 3-[4-[5-bromo-4-methyl-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664991-20-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-3-(3-pyridinyl)-2-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 664991-21-3 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-3-(3-pyridinyl)-2-(1H-pyrrol-3-yl)-
(9CI) (CA INDEX NAME)



RN 664991-22-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-3-(3-pyridinyl)-2-(1H-pyrrol-3-yl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-21-3
CMF C16 H11 Cl N4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-23-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-4-methoxy-3-(3-pyridinyl)-2-(1H-pyrrol-
3-yl)- (9CI) (CA INDEX NAME)



RN 664991-24-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-4-methoxy-3-(3-pyridinyl)-2-(1H-pyrrol-3-yl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-23-5
CMF C17 H13 Cl N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-26-8 CAPLUS
CN Ethanamine, 2-[[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 664991-27-9 CAPLUS
CN Ethanamine, 2-[[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]oxy]-N-methyl-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-26-8
CMF C19 H17 Cl N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-28-0 CAPLUS
CN 1,3-Propanediamine, N-[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]-N,N',N'-trimethyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 664991-29-1 CAPLUS
CN 1,3-Propanediamine, N'-[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664991-30-4 CAPLUS
CN 1,3-Propanediamine, N'-[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]-N,N-dimethyl-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-29-1
CMF C21 H22 Cl N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-31-5 CAPLUS
CN 1-Propanamine, 3-[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664991-32-6 CAPLUS

CN 1-Propanamine, 3-[4-[5-chloro-4-methoxy-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664991-33-7 CAPLUS
CN Urea, [2-[[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 664991-34-8 CAPLUS
CN Urea, [2-[[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]oxy]ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-33-7
CMF C19 H16 Cl N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-35-9 CAPLUS

CN Ethanol, 2-[[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]oxy]- (9CI) (CA INDEX NAME)



RN 664991-36-0 CAPLUS
CN Ethanol, 2-[[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]oxy]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-35-9
CMF C18 H14 Cl N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-37-1 CAPLUS
CN Piperazine, 1-acetyl-4-[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 664991-38-2 CAPLUS
CN Piperazine, 1-acetyl-4-[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-37-1
CMF C22 H20 Cl N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-39-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-3-(4,5-dihydro-5-pyrimidinyl)-2-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 664991-40-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-3-(4,5-dihydro-5-pyrimidinyl)-2-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 664991-41-7 CAPLUS
CN 1-Piperazineethanol, α-[[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 664991-42-8 CAPLUS
CN 1-Piperazineethanol, α-[[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]methyl]-4-methyl-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-41-7
CMF C25 H27 Cl N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-43-9 CAPLUS
CN 2-Propanol, 1-[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 664991-44-0 CAPLUS
CN 2-Propanol, 1-[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-3-(dimethylamino)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-43-9
CMF C22 H22 Cl N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-45-1 CAPLUS
CN 4-Morpholineethanol, α-[[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 664991-46-2 CAPLUS
CN 4-Morpholineethanol, α-[[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-45-1
CMF C24 H24 Cl N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-47-3 CAPLUS
CN 1-Pyrrolidineethanol, α-[[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]methyl]-3-hydroxy- (9CI) (CA INDEX NAME)



RN 664991-48-4 CAPLUS
CN 1-Pyrrolidineethanol, α-[[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]methyl]-3-hydroxy-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-47-3
CMF C24 H24 Cl N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-49-5 CAPLUS
CN [1,4'-Bipiperidine]-1'-ethanol, α-[[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 664991-50-8 CAPLUS
CN [1,4'-Bipiperidine]-1'-ethanol, α-[[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664991-49-5
CMF C30 H35 Cl N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 664991-51-9 CAPLUS
CN 1-Propanamine, 3-[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenoxy]-2-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 664991-52-0 CAPLUS
CN 1-Piperazineethanamine, N-[4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 664991-53-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-2-(1H-pyrazol-4-yl)-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 664991-54-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-4-amine, 5-chloro-2-[4-[3-(dimethylamino)propoxy]phenyl]-N-methyl-3-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 664991-91-7 CAPLUS
CN 2-Propanol, 1-[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenoxy]-3-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 664991-92-8 CAPLUS
CN 1-Pyrrolidineethanol, α-[[4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 664991-93-9 CAPLUS
CN 1,3-Propanediamine, N-[5-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-2-pyridinyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)



IT 663884-08-0P, 4-(5-Bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenol 664991-67-7P 664991-87-1P
664991-88-2P 664991-89-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted pyrrolopyridines as Itk kinase inhibitors)

RN 663884-08-0 CAPLUS
CN Phenol, 4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 664991-67-7 CAPLUS
CN Phenol, 4-[5-bromo-2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 664991-87-1 CAPLUS
CN Benzenamine, N-(2-chloroethyl)-4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 664991-88-2 CAPLUS
CN Benzenamine, 4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 664991-89-3 CAPLUS
CN Carbamic acid, [4-[5-chloro-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:162597 CAPLUS
DOCUMENT NUMBER: 140:210763
TITLE: Use of inducible T cell kinase (ITK) inhibitors for the treatment of mast cell-driven or basophil-driven diseases
INVENTOR(S): Ericsson, Per-Olof; Kristensson, Karin; Sideras, Paschalis; Sjo, Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016270	A1	20040226	WO 2003-SE1274	20030813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003251271	A1	20040303	AU 2003-251271	20030813
PRIORITY APPLN. INFO.:			SE 2002-2464 A	20020814
			WO 2003-SE1274 W	20030813

AB The invention relates to the treatment of mast cell-driven or basophil-driven conditions or diseases by inhibiting the activity of inducible T cell kinase (ITK). Particular conditions or diseases that may be treated include asthma, rhinitis, and chronic obstructive pulmonary disease. Preparation of e.g. 5-bromo-3-(4-morpholin-4-ylphenyl)-2-phenyl-1H-pyrrolo[2,3-b]pyridine is described.

IT 663884-05-7P 663884-07-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inducible T cell kinase (ITK) inhibitors for the treatment of mast cell-driven or basophil-driven diseases)

RN 663884-05-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-(4-morpholinyl)phenyl]-2-phenyl-

(9CI) (CA INDEX NAME)



RN 663884-07-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 663884-06-8
CMF C25 H24 Br N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 663884-06-8 663884-08-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(inducible T cell kinase (ITK) inhibitors for the treatment of mast cell-driven or basophil-driven diseases)
RN 663884-06-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 663884-08-0 CAPLUS
CN Phenol, 4-(5-bromo-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:99280 CAPLUS
DOCUMENT NUMBER: 140:339244
TITLE: Benzimidazolone p38 inhibitors
AUTHOR(S): Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.; Barberia, John T.; Carty, Thomas J.; Cortina, Santo R.; Csiki, Csilla; Dipesa, Alan J.; Elliott, Nancy C.; Gabel, Christopher A.; Jordan, Crystal K.; Labasi, Jeff M.; Martin, William H.; Peese, Kevin M.; Stock, Ingrid A.; Svensson, Linne; Sweeney, Francis J.; Yu, Chul H.
CORPORATE SOURCE: Pfizer Global Research and Development, Groton Laboratories, Groton, CT, 06340, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(4), 919-923
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:339244

AB The synthesis and in vitro p38α activity of a novel series of benzimidazolone inhibitors is described. The p38α SAR is consistent with a mode of binding wherein the benzimidazolone carbonyl serves as the H-bond acceptor to Met109 of p38α in a manner analogous to the pyridine nitrogen of prototypical pyridylimidazole p38 inhibitors. Potent p38α activity comparable to that of several previously reported p38 inhibitors is observed for this novel chemotype.

IT 680189-37-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and in vitro p38 structure activity of benzimidazolone inhibitors)
RN 680189-37-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[6-amino-2-(3-methylphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-1,3-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:841207 CAPLUS
DOCUMENT NUMBER: 139:337961
TITLE: Preparation of pyrrolopyridines, their radioactive iodine-substituted derivatives, and their use as imaging agents and antitumor agents targeting p38MAPK
INVENTOR(S): Omomo, Yoshio; Hirata, Masahiko; Yao, Ryuma
PATENT ASSIGNEE(S): Daiichi Radioisotope Laboratories, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003306489	A	20031028	JP 2002-111907	20020415
PRIORITY APPLN. INFO.:			JP 2002-111907	20020415
OTHER SOURCE(S):	MARPAT 139:337961			

GI



I

AB Radioactive pyrrolopyridines I (R1 or R2 = radioactive iodine; the other = H) are prepared by treatment of I (R1 or R2 = iodine, trialkyltin, trialkylsilyl; the other = H) with alkali metal radioactive iodide. Thus, m-iodo-N-methoxy-N-methylbenzamide was treated with 4-(tert-Butyldimethylsilyloxy)pyridine in the presence of LDA, then the crude product was refluxed with 4-benzyloxy-2,6-diaminopyridine and H2SO4 in ethylene glycol di-Me ether for 6 h to give I (R1 = iodine, R2 = H), which inhibited p38MAPK with IC50 value of 4.8 nM. In B 16 melanoma-bearing mice, 1.79% I (R1 = 125I, R2 = H) accumulated in the tumor 1 h after i.v. administration.

IT 616204-18-3P
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of radioactive I-substituted pyrrolopyridines for imaging agents and antitumor agents targeting p38MAPK)

RN 616204-18-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-[3-(iodo-125I)phenyl]-4-(phenylmethoxy)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT 616204-17-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of radioactive I-substituted pyrrolopyridines for imaging agents and antitumor agents targeting p38MAPK)
RN 616204-17-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(3-iodophenyl)-4-(phenylmethoxy)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT 616204-19-4P 616204-20-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of radioactive I-substituted pyrrolopyridines for imaging agents and antitumor agents targeting p38MAPK)
RN 616204-19-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-iodophenyl)-4-(phenylmethoxy)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 616204-20-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 4-(phenylmethoxy)-3-(4-pyridinyl)-2-[3-(tributylstannyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:91269 CAPLUS
DOCUMENT NUMBER: 139:62596
TITLE: Imidazopyrimidines, potent inhibitors of p38 MAP kinase
AUTHOR(S): Rupert, Kenneth C.; Henry, James R.; Dodd, John H.; Wadsworth, Scott A.; Cavender, Druie E.; Olini, Gilbert C.; Fahmy, Bohumila; Siekierka, John J.
CORPORATE SOURCE: L.L.C., Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ, 08869, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(3), 347-350
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:62596

AB The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

IT 215306-39-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(imidazopyrimidines as potent inhibitors of p38 MAP kinase)
RN 215306-39-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:5957 CAPLUS
DOCUMENT NUMBER: 138:55984
TITLE: Preparation of azaindoles as protein kinase inhibitors
INVENTOR(S): Cox, Paul Joseph; Majid, Tahir Nadeem; Lai, Justine

Yeun Quai; Morley, Andrew; Amendola, Shelley; Deprets, Stephanie Daniele; Edlin, Chris; Gardner, Charles J.; Kominos, Dorothea; Pedgrift, Brian Leslie; Halley, Frank; Gillespy, Timothy Alan; Edwards, Michael; Clerc, Francois Frederic; Nemecek, Conception; Houille, Olivier; Damour, Dominique; Bouchard, Herve; Bezard, Daniel; Carrez, Chantal

PATENT ASSIGNEE(S): Aventis Pharma Limited, UK
SOURCE: PCT Int. Appl., 373 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000688	A1	20030103	WO 2002-GB2799	20020620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2451678	A1	20030103	CA 2002-2451678	20020620
EP 1397360	A1	20040317	EP 2002-730531	20020620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200400015	A	20040415	EE 2004-15	20020620
BR 2002010507	A	20040615	BR 2002-10507	20020620
SI 21462	A	20041031	SI 2002-20015	20020620
JP 2004534826	T	20041118	JP 2003-507091	20020620
HU 200400247	A2	20050128	HU 2004-247	20020620
CN 1665809	A	20050907	CN 2002-812476	20020620
NZ 529205	A	20060428	NZ 2002-529205	20020620
US 2004053931	A1	20040318	US 2002-177804	20020621
US 6897207	B2	20050524		
ZA 2003009648	A	20050311	ZA 2003-9648	20031211
BG 108481	A	20050531	BG 2003-108481	20031219
US 2005267304	A1	20051201	US 2004-995103	20041123
PRIORITY APPLN. INFO.:			GB 2001-15109 A	20010621
			US 2001-300257P P	20010622
			WO 2002-GB2799 W	20020620
			US 2002-177804 A1	20020621

OTHER SOURCE(S): MARPAT 138:55984
GI



I

AB The invention is directed to physiol. active azaindoles (shown as I; variables defined below; e.g. 6-(5-methoxy-1-methyl-1H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine) and compns. containing such compds.; and their

prodrugs, and pharmaceutically acceptable salts and solvates of such compds. and their prodrugs. Such compds. and compns. have valuable pharmaceutical properties, in particular the ability to inhibit kinases, especially Syk, FAK, KDR, Aurora2 and IGF1R (data given in general rather than for specific I). Although the methods of preparation are not claimed, >100 example prepns. of intermediates and I are included. For I: R1 = aryl or heteroaryl each optionally substituted by ≥1 groups = alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, R4, -C(O)R, -C(O)OR5, -C(O)NY1Y2, -NY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)C(O)OR7, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -SO2NY1Y2 and -Z2R. R2 = H, acyl, cyano, halo, lower alkenyl, -Z2R4, -SO2NY3Y4, -NY1Y2 or lower alkyl optionally substituted by aryl, cyano, heteroaryl, heterocycloalkyl, hydroxy, -Z2R4, -C(O)NY1Y2, -C(O)R, -CO2R8, -NY3Y4, -N(R6)C(O)R, -N(R6)C(O)NY1Y2, -N(R6)C(O)OR7, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -SO2NY1Y2 and ≥1 halogen atoms. R3 = H, aryl, cyano, halo, heteroaryl, lower alkyl, -Z2R4, -C(O)OR5 or -C(O)NY3Y4. R4 = alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO (or a 5- 6- or 7-membered cyclic acetal derivative thereof), -C(O)NY1Y2, -C(O)OR5, -NY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -Z3R7 and ≥1 hydroxy, alkoxy and carboxy. R5 = H, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl. R6 = H or lower alkyl; R7 = alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R8 = H or lower alkyl. R = aryl or heteroaryl; alkenyl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO (or a 5- 6- or 7-membered cyclic acetal derivative thereof), -C(O)NY1Y2, -C(O)OR5, -NY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -Z3R7 and ≥1 hydroxy, alkoxy and carboxy. X1 = N, CH, C-aryl, C-heteroaryl, C-heterocycloalkyl, C-heterocycloalkenyl, C-halo, C-CN, C-R4, CNY1Y2, COH, CZ2R, CC(O)R, CC(O)OR5, CC(O)NY1Y2, CN(R8)C(O)R, CN(R6)C(O)OR7, CN(R6)C(O)NY3Y4, CN(R6)SO2NY3Y4, CN(R6)SO2R, CSO2NY3Y4, C-NO2, or C-alkenyl or C-alkynyl optionally substituted by ≥1 aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, -C(O)NY1Y2, -C(O)OR5, -NNY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)C(O)OR7, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -SO2NY1Y2 and -Z2R4. Y1 and Y2 = H, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by ≥1 aryl, halo, heteroaryl, heterocycloalkyl, hydroxy, -C(O)NY3Y4, -C(O)OR5, NY3Y4, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)SO2R7, -N(R6)SO2NY3Y4 and -OR7, or the group -NY1Y2 may form a cyclic amine. Y3 and Y4 = H, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY3Y4 may form a cyclic amine; Z1 = O or S; Z2 = O or S(O)n; Z3 = O, S(O)n, NR6; n = 0-2.

IT 479551-40-1P, 2,3-Bis(5-Methoxyindol-3-yl)-1H-pyrrolo[2,3-b]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of azaindoles as protein kinase inhibitors with therapeutic uses)

RN 479551-40-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-bis(5-methoxy-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:594816 CAPLUS
DOCUMENT NUMBER: 137:135120
TITLE: Use of CSBP/p38 inhibitors for the treatment of inflammation-enhanced cough
INVENTOR(S): Griswold, Don E.; Underwood, David C.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060869	A2	20020808	WO 2001-US50629	20011019
WO 2002060869	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002248269	A1	20020812	AU 2002-248269	20011019
EP 1337255	A2	20030827	EP 2001-997150	20011019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004530648	T	20041007	JP 2002-561020	20011019
US 2004097473	A1	20040520	US 2003-399579	20030418
PRIORITY APPLN. INFO.:			US 2000-241564P P	20001019
			WO 2001-US50629 W	20011019

AB The invention discloses the use of a CSBP/p38 inhibitor for the treatment and prophylaxis of inflammation-enhanced cough in a mammal in need thereof.

IT 215306-39-1, RWJ 68354
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CSBP/p38 inhibitors for treatment of inflammation-enhanced cough)

RN 215306-39-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:314904 CAPLUS
DOCUMENT NUMBER: 136:319434
TITLE: Use of p38 inhibitors for the treatment of smoke inhalation
INVENTOR(S): Griswold, Don E.; Underwood, David C.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032862	A2	20020425	WO 2001-US50429	20011019
WO 2002032862	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002031283	A5	20020429	AU 2002-31283	20011019
EP 1337250	A2	20030827	EP 2001-987743	20011019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004511542	T	20040415	JP 2002-536046	20011019
US 2004092532	A1	20040513	US 2003-399580	20030418
PRIORITY APPLN. INFO.:			US 2000-241568P P	20001019
			WO 2001-US50429 W	20011019

AB The present invention is directed to the novel use of a CSBP/p38 inhibitor for the treatment, including prophylaxis of smoke induced pathol. resulting from acute and chronic inflammation in the lung. In the example provided, the p38 MAP kinase inhibitor trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4-yl]imidazole inhibited airway inflammation caused by tobacco smoke inhalation in mice. The p38 MAP kinase inhibitors are also useful in inflammations caused by other types of smoke and in such inflammations exacerbated by underlying conditions such as asthma and pneumonia.

IT 215306-39-1, RWJ 68354
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of p38 inhibitors combined with other agents for treatment of airway inflammation from smoke inhalation)

RN 215306-39-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:122786 CAPLUS
DOCUMENT NUMBER: 136:177996
TITLE: 2-Pyridinamine compositions and methods using them as neuroprotectants
INVENTOR(S): Grant, Elfrida R.; Brown, Frank K.; Zivin, Robert Allan; McMillan, Michael; Zhong, Zhong; Benjamin, Daniel
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011724	A2	20020214	WO 2001-US41565	20010806
WO 2002011724	A3	20020815		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418912	A1	20020214	CA 2001-2418912	20010806
AU 2001078206	A5	20020218	AU 2001-78206	20010806
US 2002198219	A1	20021226	US 2001-922658	20010806
EP 1317266	A2	20030611	EP 2001-956179	20010806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013148	A	20030708	BR 2001-13148	20010806
JP 2004510707	T	20040408	JP 2002-517060	20010806
NZ 524101	A	20041126	NZ 2001-524101	20010806
CN 1635890	A	20050706	CN 2001-816691	20010806
ZA 2003001861	A	20040707	ZA 2003-1861	20030306
US 2003225085	A1	20031204	US 2003-402094	20030328
PRIORITY APPLN. INFO.:			US 2000-223795P	P 20000808
			US 2001-922658	B3 20010806
			WO 2001-US41565	W 20010806

OTHER SOURCE(S): MARPAT 136:177996

AB The invention provides neuroprotective pharmaceutical compns. comprising 2-pyridinamines. The invention also provides methods of using these compns. to prevent ischemic cell death, particularly neuronal cell death, and reduce the likelihood of neuronal cell death in a subject due to a traumatic event. The invention further provides an apparatus for administering the pharmaceutical compns to a subject.

IT 208104-11-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(pyridinamine compds. for neuroprotectants)
RN 208104-11-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:483654 CAPLUS
DOCUMENT NUMBER: 135:133334
TITLE: Protection against glutamate toxicity through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells
AUTHOR(S): Grant, E. R.; Errico, M. A.; Emanuel, S. L.; Benjamin, D.; McMillian, M. K.; Wadsworth, S. A.; Zivin, R. A.; Zhong, Z.
CORPORATE SOURCE: Drug Discovery, R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, 08869, USA
SOURCE: Biochemical Pharmacology (2001), 62(3), 283-296
CODEN: BCPCA6; ISSN: 0006-2952
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Excessive levels of the neurotransmitter glutamate trigger excitotoxic processes in neurons that lead to cell death. N-Methyl-D-aspartate (NMDA) receptor over-activation is a key excitotoxic stimulus that leads to increases in intracellular calcium and activation of downstream signaling pathways, including the p44/42 mitogen-activated protein (MAP) kinase pathway. In the present study, the authors have demonstrated that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a potent and selective inhibitor of the p44/42 MAP kinase signaling pathway, prevents glutamate-induced death in neuronally differentiated P19 cells. In addition, the authors show that differentiated, but not undifferentiated, P19 cells expressed zeta1, epsilon1, and epsilon2 subunits of the NMDA receptor. Differentiated P19 cells exhibited specific NMDA receptor binding and intracellular calcium responses to glutamate that were blocked by the selective NMDA receptor antagonist [5R,10S]-[+]-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), but not U0126. Glutamate treatment of differentiated P19 cells triggered a rapid and sustained induction in p42 MAP kinase phosphorylation that was blocked by U0126. Pretreatment of differentiated P19 cells with U0126, but not other classes of protein kinase inhibitors, protected against glutamate-induced cell death. Post-treatment with U0126, even as late as 6 h after glutamate application, also protected against glutamate toxicity. These results suggest that the p44/42 MAP kinase pathway may be a critical downstream signaling pathway in glutamate receptor-activated toxicity.
IT 215306-39-1, 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)-
RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)

(p38 MAPK inhibitor; glutamate toxicity protection through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells)

RN 215306-39-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:326267 CAPLUS

DOCUMENT NUMBER: 134:340435

TITLE: Preparation and activation effect of indoles to estrogen receptor

INVENTOR(S): Kato, Susumu; Hayakawa, Kazuhide; Fujii, Akihiko

PATENT ASSIGNEE(S): Japan Tobacco, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001122855	A	20010508	JP 1999-305996	19991027

PRIORITY APPLN. INFO.: JP 1999-305996 19991027

OTHER SOURCE(S): MARPAT 134:340435

GI



I



II

AB Title compds. [I; R1 = H, alkyl; R5, R6 independently = H, halo, OH, alkyl, alkoxy; R7 = H, halo, alkyl; A, B, D, E, F independently = N, CH; Y = benzene] and pharmaceutically acceptable salts, having activation effect for estrogen receptor-β, are prepared and are useful as osteoporosis remedy without side effect. Thus, the title compound II was prepared and biol. tested.

IT 338466-14-1P 338468-65-8P 338468-73-8P
338469-00-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and activation effect of indoles to estrogen receptor)

RN 338466-14-1 CAPLUS

CN Phenol, 2-fluoro-4-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 338468-65-8 CAPLUS

CN Phenol, 4-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 338468-73-8 CAPLUS
CN Phenol, 2-fluoro-4-(7-oxido-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 338469-00-4 CAPLUS
CN Phenol, 4-(7-oxido-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 338466-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and activation effect of indoles to estrogen receptor)
RN 338466-29-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[3-fluoro-4-(phenylmethoxy)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:208067 CAPLUS
DOCUMENT NUMBER: 134:242657
TITLE: Use of CSAIDs (cytokine suppressive antiinflammatory drugs) in rhinovirus infection
INVENTOR(S): Dillon, Susan B.; Griego, Sandra D.
PATENT ASSIGNEE(S): Smithkline Beecham Corp., USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019322	A2	20010322	WO 2000-US25386	20000915
WO 2001019322	A3	20011004		

W: AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM,

HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2385722	A1	20010322	CA 2000-2385722	20000915
AU 2000075845	A	20010417	AU 2000-75845	20000915
EP 1223924	A2	20020724	EP 2000-965060	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200200673	T2	20021223	TR 2002-673	20000915
JP 2003516314	T	20030513	JP 2001-522960	20000915
HU 200204333	A2	20030528	HU 2002-4333	20000915
BR 2000014041	A	20030715	BR 2000-14041	20000915
ZA 2002002060	A	20030312	ZA 2002-2060	20020313
NO 2002001301	A	20020516	NO 2002-1301	20020315
PRIORITY APPLN. INFO.:			US 1999-154494P P	19990917
			WO 2000-US25386 W	20000915

AB The present invention is directed to the novel use of a CSBP/p38 kinase inhibitor for the treatment of symptoms of the common cold and the exacerbation of symptoms associated therewith in humans. The effect of a compound trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4-yl]imidazole on the rhinovirus-induced cytokine production by epithelial cells was examined

IT 215306-39-1, RWJ 68354
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytokine suppressive antiinflammatory drugs (CSAIDs) for treatment of rhinovirus infection)

RN 215306-39-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2001:31330 CAPLUS
DOCUMENT NUMBER:	134:95509
TITLE:	Method of reducing neuronal injury or apoptosis using a p38 mitogen-activated protein kinase inhibitor
INVENTOR(S):	Lipton, Stuart A.
PATENT ASSIGNEE(S):	USA
SOURCE:	PCT Int. Appl., 34 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001986	A1	20010111	WO 2000-US18385	20000630
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				

IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2373883	A1	20010111	CA 2000-2373883	20000630
EP 1196167	A1	20020417	EP 2000-948576	20000630
EP 1196167	B1	20060419		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2003503456	T	20030128	JP 2001-507478	20000630
AU 777275	B2	20041007	AU 2000-62052	20000630
AT 323482	T	20060515	AT 2000-948576	20000630
ES 2260033	T3	20061101	ES 2000-948576	20000630
US 2003078274	A1	20030424	US 2002-115578	20020402
PRIORITY APPLN. INFO.:			US 1999-142341P	P 19990702
			US 2000-608572	B1 20000630
			WO 2000-US18385	W 20000630

OTHER SOURCE(S): MARPAT 134:95509

AB A method is provided for reducing neuronal injury or apoptosis including administering to a patient in need thereof an effective amount of a p38 mitogen-activated protein kinase (MAPK) inhibitor. Methods of treating an HIV-mediated dementia, glaucoma, or other neurodegenerative disorders are also disclosed.

IT 215306-39-1, RWJ 68354
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p38 MAPK inhibitor for reducing neuronal injury or apoptosis)

RN 215306-39-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1998:812377 CAPLUS
DOCUMENT NUMBER:	130:177125
TITLE:	Potent inhibitors of the MAP kinase p38
AUTHOR(S):	Henry, James R.; Rupert, Kenneth C.; Dodd, John H.; Turchi, Ignatius J.; Wadsworth, Scott A.; Cavender, Druie E.; Schafer, Peter H.; Siekierka, John J.
CORPORATE SOURCE:	Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ, 08869, USA
SOURCE:	Bioorganic & Medicinal Chemistry Letters (1998), 8(23), 3335-3340 CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER:	Elsevier Science Ltd.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB The MAP kinase p38 plays a key role in the biosynthesis of the

inflammatory cytokines TNF-α and IL-1. We have developed A-novel series of potent p38 inhibitors that could lead to new methods of treatment for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

IT 208104-11-4P 208104-47-6P 208104-99-8P
215306-29-9P 215306-39-1P 215306-49-3P
215306-59-5P 215307-08-7P 215307-16-7P
215307-17-8P 215307-18-9P 215307-19-0P
215307-20-3P 215307-21-4P 215307-22-5P
215307-23-6P 215307-24-7P 215307-25-8P
220519-40-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anti-inflammatory MAP kinase p38 inhibitors)

RN 208104-11-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208104-47-6 CAPLUS
CN Acetamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-99-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-N-(phenylmethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-29-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-N,N-dimethyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-39-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-49-3 CAPLUS
CN 6H-Pyrrolo[2,3-b]pyridin-6-one, 4-butoxy-2-(4-fluorophenyl)-1,7-dihydro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-59-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(3-iodophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-08-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 4-butoxy-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-16-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(3-chlorophenyl)-3-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 215307-17-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(3,4-difluorophenyl)-3-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 215307-18-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(3-chloro-4-ethoxyphenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-19-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-(3-phenylpropoxy)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-20-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-(phenylmethoxy)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-21-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-butoxy-2-(4-fluorophenyl)-6-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-22-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-[(3-methoxyphenyl)methoxy]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-23-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-[(4-fluorophenyl)methoxy]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-24-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(4-fluorophenyl)-6-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-25-8 CAPLUS
CN 6H-Pyrrolo[2,3-b]pyridin-6-one, 2-(4-fluorophenyl)-1,7-dihydro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 220519-40-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:764924 CAPLUS
DOCUMENT NUMBER: 130:95495
TITLE: Synthesis of RWJ 68354: a potent inhibitor of the MAP kinase p38
AUTHOR(S): Henry, James R.; Dodd, John H.
CORPORATE SOURCE: The R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ, 08869, USA
SOURCE: Tetrahedron Letters (1998), 39(48), 8763-8764
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The regiospecific synthesis of RWJ 68354, a potent inhibitor of the p38 MAP kinase, via a variation of the Bischler-Mohlau indole synthesis is reported.
IT 208104-12-5P
RL: BYP (Byproduct); PREP (Preparation)
(preparation of RWJ 68354)
RN 208104-12-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 3-(4-fluorophenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT 208104-11-4P 215306-39-1P 215307-08-7P
219537-20-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of RWJ 68354)

RN 208104-11-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 215306-39-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-08-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 4-butoxy-2-(4-fluorophenyl)-3-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 219537-20-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-phenoxy-3-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:709078 CAPLUS
DOCUMENT NUMBER: 129:330657
TITLE: Preparation of substituted pyrrolopyridines for the treatment of inflammatory diseases
INVENTOR(S): Dodd, John H.; Henry, James R.; Rupert, Kenneth
PATENT ASSIGNEE(S): Ortho-McNeil Corporation, Inc., USA
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9847899	A1	19981029	WO 1998-US7831		19980417
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9871329	A	19981113	AU 1998-71329		19980417
ZA 9803452	A	19991025	ZA 1998-3452		19980423
PRIORITY APPLN. INFO.:			US 1997-44244P	P	19970424
			WO 1998-US7831	W	19980417

OTHER SOURCE(S): MARPAT 129:330657
GI



I

AB The title compds. [I; R1 = NH2. (C1-5 alkyl)amino, OH, etc.; R2 = H, halo, phenyl(C1-5 alkyl), substituted Ph; R3 = H, OH, C1-5 alkoxy, etc.; R4 = N, C; R5 = (un)substituted Ph; R6 = H, C1-5 alkyl, di(C1-5 alkyl)amino] which inhibit the production of a number of inflammatory cytokines such as IL-1β and TNF-α, and are useful in the treatment of diseases associated with overprodn. of inflammatory cytokines, were prepared Thus, reaction of 2,6-diaminopyridine with 2{[(1,1-dimethylethyl)dimethylsilyl]oxy}-1-(4-fluorophenyl)-2-(4-pyridyl)ethanone in the presence of concentrate H2SO4 in DME afforded I [R1 = NH2; R2 = R3 = H; R4 = C; R5 = 4-FC6H4; R6 = H] which showed IC50 of 2.0 μM against enzyme p38 and IC50 of 33 nM against TNF-α production

IT 208104-11-4P 215306-39-1P 215307-08-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted pyrrolopyridines for the treatment of inflammatory diseases)

RN 208104-11-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-39-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-08-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 4-butoxy-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT 208104-47-6P 208104-99-8P 208105-06-0P
215306-29-9P 215306-36-8P 215306-43-7P
215306-46-0P 215306-49-3P 215306-59-5P
215307-16-7P 215307-17-8P 215307-18-9P
215307-19-0P 215307-20-3P 215307-21-4P
215307-22-5P 215307-23-6P 215307-24-7P
215307-25-8P 215307-26-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyrrolopyridines for the treatment of inflammatory diseases)

RN 208104-47-6 CAPLUS

CN Acetamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-99-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-N-(phenylmethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-06-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 5-bromo-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-29-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-N,N-dimethyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-36-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-5-(phenylmethyl)-3-(4-

pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-43-7 CAPLUS
CN Methanimidamide, N'-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 215306-46-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(4-fluorophenyl)-4,6-dimethoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-49-3 CAPLUS
CN 6H-Pyrrolo[2,3-b]pyridin-6-one, 4-butoxy-2-(4-fluorophenyl)-1,7-dihydro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-59-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(3-iodophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-16-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(3-chlorophenyl)-3-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 215307-17-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(3,4-difluorophenyl)-3-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 215307-18-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(3-chloro-4-ethoxyphenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-19-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-(3-phenylpropoxy)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-20-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-(phenylmethoxy)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-21-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-butoxy-2-(4-fluorophenyl)-6-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-22-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-[(3-methoxyphenyl)methoxy]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-23-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-[(4-fluorophenyl)methoxy]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-24-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(4-fluorophenyl)-6-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-25-8 CAPLUS
CN 6H-Pyrrolo[2,3-b]pyridin-6-one, 2-(4-fluorophenyl)-1,7-dihydro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-26-9 CAPLUS
CN Propanamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:636331 CAPLUS
DOCUMENT NUMBER: 130:20195
TITLE: 6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): A Potent and Selective p38 Kinase Inhibitor
AUTHOR(S): Henry, James R.; Rupert, Kenneth C.; Dodd, John H.; Turchi, Ignatius J.; Wadsworth, Scott A.; Cavender, Druie E.; Fahmy, Bohumila; Olini, Gilbert C.; Davis, Janet E.; Pellegrino-Gensey, J. Lee; Schafer, Peter H.; Siekierka, John J.
CORPORATE SOURCE: The R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, 08869, USA
SOURCE: Journal of Medicinal Chemistry (1998), 41(22), 4196-4198
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:20195

AB The authors showed RWJ 68354 (I) to be a potent inhibitor of cellular p38 kinase activity (9 nM), LPS-stimulated tumor necrosis factor-α (TNF-α)/interleukin-1β (IL-1β) production from human peripheral blood mononuclear cells (6.3 nM/26 nM) and LPS-induced TNF-α production in mice (ED50 < 10 mg/kg) and in rats (ED50 < 25 mg/kg). I was shown to directly inhibit natural activated p38 and partially activated p38 kinase. Structure-activity relations of I with some analogs is described. Thus, I is a promising candidate for further preclin. evaluation.

IT 208104-11-4P 215306-39-1P 215307-08-7P
215307-19-0P 215307-20-3P 215307-22-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(6-amino(4-fluorophenyl)methoxy 4-pyridyl-1H-pyrrolo[b]pyridine (RWJ 68354) as potent and selective p38 kinase inhibitor which releases tumor necrosis factor-α and interleukin-1β and structure-activity relations)

RN 208104-11-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215306-39-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-08-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 4-butoxy-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-19-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-(3-phenylpropoxy)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-20-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-(phenylmethoxy)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 215307-22-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-4-[(3-methoxyphenyl)methoxy]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:352830 CAPLUS
DOCUMENT NUMBER: 129:27933
TITLE: Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
INVENTOR(S): Zablocki, Jeffery A.; Tarlton, Eugene, Jr.; Rizzi, James P.; Mantlo, Nathan B.
PATENT ASSIGNEE(S): Amgen Inc., USA; Zablocki, Jeffery A.; Tarlton, Eugene, Jr.; Rizzi, James P.; Mantlo, Nathan B.
SOURCE: PCT Int. Appl., 258 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9822457	A1	19980528	WO 1997-US21344	19971118
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2271767	A1	19980528	CA 1997-2271767	19971118
AU 9852659	A	19980610	AU 1998-52659	19971118
AU 734841	B2	20010621		
EP 948495	A1	19991013	EP 1997-947617	19971118
EP 948495	B1	20040414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1246856	A	20000308	CN 1997-181372	19971118
JP 2001506980	T	20010529	JP 1998-523914	19971118
AT 264318	T	20040415	AT 1997-947617	19971118
PT 948495	T	20040831	PT 1997-947617	19971118
ES 2215242	T3	20041001	ES 1997-947617	19971118
MX 9904598	A	20000228	MX 1999-4598	19990518
KR 2000057137	A	20000915	KR 1999-704405	19990519
US 6180643	B1	20010130	US 1999-269600	19990608
US 6440973	B1	20020827	US 2000-644102	20000823
US 2003096819	A1	20030522	US 2002-175182	20020618
US 6605634	B2	20030812		

PRIORITY APPLN. INFO.:	US 1996-31207P	P	19961119
	WO 1997-US21344	W	19971118
	US 1999-269600	A3	19990608
	US 2000-644102	A3	20000823

OTHER SOURCE(S): MARPAT 129:27933
GI



I II

AB The invention comprises a new class of novel aryl- and heteroaryl-substituted fused pyrrole compds. I [W, X, Q, T = N, CH, CR1-4; R1-4 = -Z-Y with provisos; Z = bond, alk(ane/ene/yne)diyl, heterocyclediyl, (hetero)arylene; Y = H (when Z ≠ bond), halo, cyano, NO2, various acyl, (un)substituted OH, SH, or NH2; R10 = H, (un)substituted alk(en/yn)yl, various acyl or sulfonyl groups; R11, R12 = (un)substituted (hetero)aryl]. The compds. are useful for the prophylaxis

and treatment of diseases or conditions mediated by TNF-α, IL-1β, IL-6 and/or IL-8, and other maladies, such as pain and diabetes. In particular, the compds. are useful for prophylaxis and treatment of inflammatory diseases or conditions. The invention also comprises pharmaceutical compns., methods of prophylaxis and treatment, use of compds. and compns., and intermediates and preparatory processes. For instance, amidation of 4-(2-aminobenzoyl)pyridine with 4-fluorobenzoyl chloride, and cyclization of the resultant keto amide using low-valent Ti from K/graphite/TiCl3, gave title compound II. This compound inhibited cyclooxygenase in vitro with an IC50 of ≤ 5 μM.

IT 208104-44-3P 208104-78-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryl- and heteroaryl-substituted, fused pyrrole antiinflammatory agents)

RN 208104-44-3 CAPLUS
CN Carbamic acid, [2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 208104-78-3 CAPLUS
CN Carbamic acid, [(1S)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 208104-11-4P 208104-12-5P 208104-13-6P
208104-15-8P 208104-16-9P 208104-17-0P
208104-18-1P 208104-19-2P 208104-20-5P

208104-21-6P 208104-22-7P 208104-23-8P
208104-24-9P 208104-25-0P 208104-26-1P
208104-27-2P 208104-28-3P 208104-29-4P
208104-30-7P 208104-31-8P 208104-32-9P
208104-33-0P 208104-34-1P 208104-35-2P
208104-36-3P 208104-37-4P 208104-38-5P
208104-39-6P 208104-40-9P 208104-41-0P
208104-42-1P 208104-43-2P 208104-45-4P
208104-46-5P 208104-47-6P 208104-48-7P
208104-49-8P 208104-50-1P 208104-51-2P
208104-53-4P 208104-54-5P 208104-55-6P
208104-56-7P 208104-57-8P 208104-58-9P
208104-59-0P 208104-60-3P 208104-61-4P
208104-62-5P 208104-63-6P 208104-64-7P
208104-65-8P 208104-66-9P 208104-67-0P
208104-68-1P 208104-69-2P 208104-70-5P
208104-71-6P 208104-73-8P 208104-75-0P
208104-77-2P 208104-79-4P 208104-80-7P
208104-81-8P 208104-82-9P 208104-83-0P
208104-84-1P 208104-85-2P 208104-86-3P
208104-87-4P 208104-88-5P 208104-89-6P
208104-90-9P 208104-91-0P 208104-92-1P
208104-93-2P 208104-94-3P 208104-95-4P
208104-96-5P 208104-97-6P 208104-99-8P
208105-00-4P 208105-01-5P 208105-02-6P
208105-03-7P 208105-04-8P 208105-05-9P
208105-06-0P 208105-07-1P 208105-08-2P
208105-09-3P 208105-10-6P 208105-11-7P
208105-12-8P 208105-13-9P 208105-14-0P
208105-16-2P 208105-17-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl- and heteroaryl-substituted, fused pyrrole antiinflammatory agents)

RN 208104-11-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208104-12-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 3-(4-fluorophenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208104-13-6 CAPLUS
CN Carbamic acid, [4-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 208104-15-8 CAPLUS
CN Butanamide, 4-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-16-9 CAPLUS
CN Carbamic acid, [(1S)-4-[(aminocarbonyl)amino]-1-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-17-0 CAPLUS
CN Pentanamide, 2-amino-5-[(aminocarbonyl)amino]-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-18-1 CAPLUS
CN Carbamic acid, [(1S)-1-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-1,5-pentanediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-19-2 CAPLUS
CN Hexanamide, 2,6-diamino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-20-5 CAPLUS
CN Carbamic acid, [(1S)-1-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-1,4-butanediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-21-6 CAPLUS
CN Pentanamide, 2,5-diamino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-22-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-1-[(4-iodophenyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-23-8 CAPLUS
CN Benzenepropanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-

pyrrolo[2,3-b]pyridin-6-yl]-4-iodo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-24-9 CAPLUS
CN Carbamic acid, [(1S)-1-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-25-0 CAPLUS
CN Butanamide, 2-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-26-1 CAPLUS

CN Carbamic acid, [(1S)-1-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-3,3-dimethylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-27-2 CAPLUS
CN Pentanamide, 2-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-4,4-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-28-3 CAPLUS
CN Carbamic acid, [5-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 208104-29-4 CAPLUS
CN Pentanamide, 5-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-30-7 CAPLUS
CN Carbamic acid, [6-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 208104-31-8 CAPLUS
CN Hexanamide, 6-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-32-9 CAPLUS
CN Carbamic acid, [(1S)-1-(cyclohexylmethyl)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-33-0 CAPLUS
CN Cyclohexanepropanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-34-1 CAPLUS
CN Pentanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-35-2 CAPLUS
CN Pentanoic acid, 4-amino-5-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-36-3 CAPLUS
CN Carbamic acid, [(1S,2R)-2-(1,1-dimethylethoxy)-1-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-37-4 CAPLUS
CN Butanamide, 2-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-3-hydroxy-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-38-5 CAPLUS
CN Carbamic acid, [2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 208104-39-6 CAPLUS
CN Benzenepropanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-40-9 CAPLUS
CN Carbamic acid, [(1S)-1-[[4-(1,1-dimethylethoxy)phenyl]methyl]-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-41-0 CAPLUS
CN Benzenepropanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-4-hydroxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-42-1 CAPLUS
CN Carbamic acid, [3-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 208104-43-2 CAPLUS
CN Propanamide, 3-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-45-4 CAPLUS
CN Acetamide, 2-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-46-5 CAPLUS
CN Methanesulfonamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-47-6 CAPLUS
CN Acetamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-48-7 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-49-8 CAPLUS

CN Benzenesulfonamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-50-1 CAPLUS
CN 2H-Isoindole-2-acetamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)



RN 208104-51-2 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)



RN 208104-53-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-54-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-55-6 CAPLUS
CN Propanamide, 2-(dimethylamino)-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-56-7 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-57-8 CAPLUS
CN Carbamic acid, [2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 208104-58-9 CAPLUS
CN Acetamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-2-(methylamino)- (9CI) (CA INDEX NAME)



RN 208104-59-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 208104-60-3 CAPLUS
CN 4-Piperidinecarboxamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 208104-61-4 CAPLUS
CN Carbamic acid, [(1S)-1-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-3-(methylsulfinyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-62-5 CAPLUS
CN Butanamide, 2-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-4-(methylsulfinyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-63-6 CAPLUS
CN Carbamic acid, [(1S)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxo-1-(3-pyridinylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-64-7 CAPLUS
CN 3-Pyridinepropanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αS)-. (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-65-8 CAPLUS
CN 1H-Imidazole-1-carboxylic acid, 5-[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-66-9 CAPLUS
CN 1H-Imidazole-4-propanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-67-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-68-1 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-69-2 CAPLUS
CN Carbamic acid, [(1R)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-70-5 CAPLUS
CN Benzeneacetamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-71-6 CAPLUS
CN Carbamic acid, [(1S)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-73-8 CAPLUS
CN Benzeneacetamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-75-0 CAPLUS
CN Carbamic acid, [(1R)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxo-1-phenylethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-77-2 CAPLUS
CN Benzeneacetamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-α-(methylamino)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-79-4 CAPLUS
CN Propanamide, 2-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-80-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-81-8 CAPLUS

CN Benzenepropanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-82-9 CAPLUS
CN Carbamic acid, [(1S)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-1-methyl-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-83-0 CAPLUS
CN Propanamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-2-(methylamino)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-84-1 CAPLUS
CN Carbamic acid, [(1S)-1-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-3-methylbutyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-85-2 CAPLUS
CN Pentanamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-4-methyl-2-(methylamino)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-86-3 CAPLUS

CN Carbamic acid, [(1R)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-87-4 CAPLUS
CN Propanamide, 2-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-88-5 CAPLUS
CN Carbamic acid, [(1S)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxo-1-(2-thienylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-89-6 CAPLUS
CN 2-Thiophenepropanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-90-9 CAPLUS
CN Carbamic acid, [(1S)-1-[(4-azidophenyl)methyl]-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-91-0 CAPLUS
CN Benzenepropanamide, α-amino-4-azido-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-92-1 CAPLUS
CN Carbamic acid, [(1S)-1-(benzo[b]thien-3-ylmethyl)-2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-93-2 CAPLUS
CN Benzo[b]thiophene-3-propanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-94-3 CAPLUS
CN Carbamic acid, [(1S)-1-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-

pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-3-phenylpropyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-95-4 CAPLUS
CN Benzenebutanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-96-5 CAPLUS
CN Carbamic acid, [(1R)-1-[[[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]carbonyl]-3-phenylpropyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-97-6 CAPLUS
CN Benzenebutanamide, α-amino-N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208104-99-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-N-(phenylmethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-00-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, N,N-diethyl-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-01-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-N-(3-phenylpropyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-02-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-N-(2-phenylpropyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-03-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, N-(2-ethylhexyl)-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-04-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 5-chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-05-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 5-fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-06-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 5-bromo-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-07-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-N,N-bis(3-methylbutyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-08-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, N-(2,2-dimethylpropyl)-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-09-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-N-(3-methylbutyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-10-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, N-(2-ethylbutyl)-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-11-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-3-(4-pyridinyl)-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 208105-12-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2-(4-fluorophenyl)-N,N-bis(3-phenylpropyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-13-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, N-ethyl-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208105-14-0 CAPLUS
CN Benzenepropanamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-α-methyl- (9CI) (CA INDEX NAME)



RN 208105-16-2 CAPLUS
CN Butanamide, N-[2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 208105-17-3 CAPLUS
CN Carbamic acid, [2-(4-fluorophenyl)-3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:522337 CAPLUS
DOCUMENT NUMBER: 99:122337
TITLE: Synthesis of a new carbonic anhydrase inhibitor
AUTHOR(S): Saify, Zafar S.
CORPORATE SOURCE: Fac. Pharm., Univ. Karachi, Karachi, 32, Pak.
SOURCE: Journal of Pharmacy (University of Karachi) (1982), 1(1), 83-8
CODEN: JPUKDX; ISSN: 0257-3865
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The sulfonamide I was prepared in 33% yield by treating the aminopyrrolopyridine with 4-AcNHC6H4SO2Cl. I has carbonic anhydrase inhibiting activity in vitro and analgesic activity at 100 mg/kg orally in mice.
IT 87022-57-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and pharmacol. activity of)

RN 87022-57-9 CAPLUS

CN Acetamide, N-[4-[[[2,3-bis(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



IT 23612-74-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with acetamidobenzenesulfonylchloride)

RN 23612-74-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1980:532395 CAPLUS

DOCUMENT NUMBER: 93:132395

TITLE: Ring opening or rearrangement versus N-oxidation in the action of peracids upon pyrrolo[2,3-b]pyridines, pyrrolo[2,3-b]pyrazines, and triazolo[1,5-a-]- and triazolo[4,3-a]pyrazine. Some chemical and spectroscopic properties of the triazolopyrazines and their N-oxides

AUTHOR(S): Hardy, Christopher R.; Parrick, John

CORPORATE SOURCE: Sch. Chem., Brunel Univ., Uxbridge, UB3 3PH, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1980), (2), 506-11
CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 93:132395

GI



I



II



III



IV

AB Peracid oxidation of the title compds. occurred by a variety of reaction pathways. E.g., the pyrrolopyridine and -pyrazines I (Z = CH, R = Me, R1 = R2 = Ph; Z = N, R = H, R1 = Ph, R2 = Me, resp.) ring-opened to give II and PhCONHCONH2, resp. In contrast, oxidation of the triazoles III (Z = N, Z1 = C; Z = C, Z1 = N, resp.) gave the resp. 7-oxides. The pyrrolopyrazine I [Z = N, R = Ac, R1R2 = (CH2)4] underwent rearrangement and N-oxidation to give the spiro compound IV. Some chemical and spectral properties of the triazolopyrazines and their N-oxides are reported.

IT 23616-69-5 74803-15-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(methylation of)

RN 23616-69-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-ol, 2,3-diphenyl-, acetate (ester) (8CI, 9CI) (CA INDEX NAME)



RN 74803-15-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-diphenyl- (6CI, 9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1977:439361 CAPLUS

DOCUMENT NUMBER: 87:39361

TITLE: Synthesis and reactions of the 1H-imidazo[1,2-a]pyrrolo[3,2-e]pyridine system

AUTHOR(S): Bancroft, Keith C. C.; Ward, Terence J.; Brown, Kevan

CORPORATE SOURCE: Sch. Chem., Leicester Polytech., Leicester, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999)

(1977), (5), 465-7
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 87:39361
GI



I II

AB 6-Amino-1H-pyrrolo[2,3-b]pyridines with α-halocarbonyl compds. gave 1H-imidazo[1,2-a]pyrrolo[3,2-e]pyridines. E.g., I (R = Me, R1 = Me, H) with BrCH2CHO under reflux in aqueous EtOH in the presence of NaHCO3 gave 88 and 52% II (R = Me, R1 = Me, H, R2 = H, resp.). The imidazopyrrolopyridines underwent bromination, acetylation, and Mannich reactions at the 3-position; when the 3-position was blocked 8-substitution occurred. E.g., bromination of II (R = Me, R1 = Me, H, R2 = H) in CHCl3 gave 20 and 48% II (R = R1 = Me, R2 = Br; R = Me, R1 = Br, R2 = H, resp.).

IT 23612-74-0 55463-74-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation reaction of, with halocarbonyl compds.)

RN 23612-74-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 55463-74-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2,3-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:4147 CAPLUS
DOCUMENT NUMBER: 82:4147

TITLE: Application of the Bischler reaction to the preparation of pyrrolopyridines and the novel dipyrrolopyridine system

AUTHOR(S): Bancroft, Keith C. C.; Ward, Terence J.; Brown, Kevan
CORPORATE SOURCE: Sch. Chem., City Leicester Polytech., Leicester, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1974), (15), 1852-8
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB The Bischler reaction of α-hydroxy ketones and 2,6-diaminopyridine gave 6-amino-1H-pyrrolo[2,3-b]pyridines and the 1,7-dihydrodipyrrolo[2,3-b:3',2'-e]pyridine system with various alkyl and aryl substituents. 2,6-Diphenyl-1,7-dihydrodipyrrolo[2,3-b:3',2'-e]-pyridine (I) underwent 3,5-disubstitution by electrophiles.

IT 55463-67-7P 55463-76-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 55463-67-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2,3-bis(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 55463-76-8 CAPLUS
CN Ethanone, 2-[(2,3-diphenyl-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-1,2-diphenyl- (9CI) (CA INDEX NAME)



IT 55463-74-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with benzoine)

RN 55463-74-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2,3-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1969:449810 CAPLUS
DOCUMENT NUMBER: 71:49810
TITLE: Syntheses and properties of 1H-pyrrolo[2,3-b] pyridines
AUTHOR(S): Herbert, R.; Wibberley, D. G.
CORPORATE SOURCE: Sch. Pharm., Sunderland Polytech., Sunderland, UK
SOURCE: Journal of the Chemical Society [Section] C: Organic (1969), (11), 1505-14
CODEN: JSOOAX; ISSN: 0022-4952
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 71:49810
GI For diagram(s), see printed CA Issue.
AB Five different routes for the preparation of 1H-pyrrolo[2,3-b]pyridines (I) were investigated. A number of 2-, 3-, and 4-alkyl and -aryl substituted derivs. were prepared by two of these methods which involved modifications of Madelung- and Fischer-syntheses of indoles. I undergo nitration, nitrosation, bromination, iodination, and reaction with Mannich bases predominantly at the 3-position although one example of nitration at the 2-position was also found. Bis[3-(1H-pyrrolo[2,3-b]-pyridyl)]methanes are formed by reaction with aldehydes, and treatment of 2-phenyl-1H-pyrrolo[2,3-b]pyridine with nitrosobenzene yields 2-phenyl-3-phenylimino-3H-pyrrolo[2,3-b]pyridine. A further example of a derivative of this isomeric 3H-system is 3-diazo-2-phenyl-3H-pyrrolo[2,3-b]pyridine which is formed from the corresponding amine by basification of the diazonium salt. 1-Substituted Grignard derivs. yield 3-iodo-compds. on treatment with H2O2 but only 1-acyl derivs. with acyl chlorides. Treatment of 2-phenyl-1H-pyrrolo[2,3-b]pyridine with CHCl3 and alkali caused ring-expansion to a 1,8-naphthyridine. A number of unexpected products were isolated both in the syntheses of the 1H-pyrrolo[2,3-b]pyridines and in their reactions with electrophiles. Ir, N.M.R., and mass spectra were used to establish all structures.
IT 23612-72-8P 23612-74-0P 23616-69-5P
23616-70-8P 23616-71-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23612-72-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-methyl-2,3-diphenyl- (8CI) (CA INDEX NAME)



RN 23612-74-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 23616-69-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-ol, 2,3-diphenyl-, acetate (ester) (8CI, 9CI) (CA INDEX NAME)



RN 23616-70-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-ol, 2,3-diphenyl- (8CI) (CA INDEX NAME)



RN 23616-71-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 6-methoxy-2,3-diphenyl- (8CI) (CA INDEX NAME)



L4 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1959:94804 CAPLUS
DOCUMENT NUMBER: 53:94804
ORIGINAL REFERENCE NO.: 53:17126h-i,17127a-i,17128a
TITLE: 7-Azaindole. V. Investigations of alternative syntheses of the ring system
AUTHOR(S): Okuda, Shigenobu; Robison, Michael M.
CORPORATE SOURCE: Amherst Coll., Amherst, MA
SOURCE: Journal of the American Chemical Society (1959), 81, 740-3
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 53:94804
AB cf. C.A. 51, 13860g. 5,6,7,8-Tetrahydro-9H-pyrido[2,3-b]indole (I) and

2,3-diphenyl-7-azaindole (II) were prepared by Fischer cyclizations of the corresponding pyridylhydrazones with polyphosphoric acid (III), though the method failed for a number of simpler pyridylhydrazones. 2-Aminopyridine-3-acetic acid (IV), obtained in low yield by a sequence from 3-(cyanomethyl)pyridine N-oxide (V), was also converted to 7-azaoxindole (VI). Cyclohexanone (VII) (4.90 g.) added to 5.45 g. 2-pyridylhydrazine (VIIa), the resulting white powder triturated with H2O, and recrystd. from cyclohexane and aqueous EtOH yielded the 2-pyridylhydrazone (VIII) of VII, m. 92-2.5° with sintering at about 85° (all m.ps. are corrected). VIII (5.68 g.) and 18 g. III heated gradually (to about 160°) to initiate the vigorous reaction, the mixture cooled, dissolved in 100 cc. H2O, washed with Et2O, neutralized with NH4OH, the product sublimed at 110°/0.2 mm. and recrystd. from aqueous EtOH yielded 2.75 g. I, m. 155-6°. I (0.001 mol), 0.1 g. 5% Pd-C, and 5 cc. Dowtherm refluxed 2 h., cooled, added to 5 cc. C6H6, filtered, extracted with warm dilute HCl, and the extract basified with NH4OH precipitated 0.14 g. 9H-pyrido[2,3-b]indole, m. 210.5-11° (C6H6). PhCH(OH)Bz (IX) (1.96 g.) in 1 cc. glacial AcOH and 1.09 g. VIIa kept 2.5 h. at room temperature and the solid deposit triturated with dilute NH4OH and EtOH gave 1.4 g. 2-pyridylhydrazone (X) of IX, b0.3 160°, m. 110°. X (1.8 g.) and 8 g. III heated 1 h. at 110-20°, cooled, stirred with 20 cc. warm H2O, and extracted with C6H6, the aqueous layer and solid basified with NH4OH, the organic layer extracted with Et2O, and the extract worked up yielded 0.21 g. II, m. 292.5-3.5° (BuOH) (sublimed at 230°/0.1 mm.). Desyl chloride (2.31 g.) in 10 cc. 95% EtOH refluxed with 0.94 g. 2-aminopyridine, the EtOH distilled, the mixture heated 1 h. at 130-40° and 5 min. to 190°, cooled, treated with H2O and NH4OH, and diluted with Me2CO precipitated 1.14 g. 2,3-diphenylimidazo[1,2-a]pyridine, plates, m. 151-1.5° (MeCN). NaCN (30 g.) in 45 cc. hot H2O treated with stirring with 250 cc. 95% EtOH and then dropwise with stirring during 40 min. with 20 g. 3-(chloromethyl)pyridine-HCl in 50 cc. 95% EtOH and 20 cc. H2O, refluxed 1 h. with stirring, evaporated in vacuo, the residue extracted with Et2O, and the extract worked up yielded 76.5-82.5% 3-(cyanomethyl)pyridine (XI), b7 126°, n20D 1.5279. XI (11.0 g.), 55 cc. glacial AcOH, and 15 cc. 30% H2O2 heated 12 h. on the steam bath, cooled to room temperature, treated again with 10 cc. H2O2, heated 8 h., diluted with 70 cc. H2O, evaporated in vacuo, treated with H2O and evaporated again repeatedly, extracted with CHCl3, and the extract worked up gave 10.8 g. V, m. 135.5-6.5° (CHCl3-C6H6). V (10.0 g.) added to 100 cc. POCl3, warmed slowly with vigorous shaking, refluxed 2 h., evaporated in vacuo, the brown sirupy residue poured onto 160 g. ice, filtered, and the residue recrystd. from Et2O-petr. ether gave 2.55 g. 2-Cl derivative (XII) of XI, m. 85-6° (Et2O-petr. ether). The strongly acidic, aqueous filtrate extracted with CHCl3, the extract worked up, and the residue chromatographed on 80 g. Al2O3 yielded 1.44 g. XII and 0.91 g. 2-chloro-5-(cyanomethyl)pyridine (XIII), m. 48-50°; the intermediate fractions combined with the recrystn. mother liquors from the XII and rechromatographed on 50 g. Al2O3 yielded an addnl. 0.52 g. XII, 0.65 g. XIII, and 0.7 g. XII-XIII mixture; the crude XIII recrystd. from Et2O-petr. ether gave pure XIII, m. 51-2°. The aqueous layer from the CHCl3 extns. adjusted to pH 4 with NH4OH and extracted with CHCl3, basified with NH4OH and again extracted, and the extract worked up gave only intractable tars; the aqueous layer evaporated to dryness in vacuo, the residue extracted with boiling Me2CO, and the extract evaporated gave 0.78 g. 3-hydroxy-5-(cyanomethyl)pyridine (XIV), m. 180-1° (C6H6-Me2CO), orange-red with FeCl3. XII (0.5 g.) and 20 cc. concentrated HCl refluxed 5.5 h. and evaporated

to dryness in vacuo, the residue triturated with H2O, dissolved in dilute aqueous NaHCO3, filtered, and repptd. with acid gave 0.43 g. 2-chloro-3-pyridineacetic acid (XV), m. 203-4° (C6H6). XII (265 mg.) and 614 mg. KMnO4 in 20 cc. H2O heated 20 min. on the steam bath, filtered, saturated with CO2, evaporated in vacuo, the residue dissolved in H2O, filtered, repptd. with acid, and recrystd. from H2O yielded 232 mg. 2-chloronicotinic acid, m. 192-3° (decomposition). XIII oxidized similarly yielded 50% 6-chloronicotinic acid, m. 198-9°. XIV (0.35 g.) and 10 cc. concentrated HCl refluxed 5 h., evaporated in vacuo, the residue dissolved in 10 cc. H2O, treated with saturated aqueous Cu(OAc)2, the precipitate filterd off, washed with a small amount cold H2O, suspended in 40 cc. MeOH, treated with H2S, filtered, and evaporated, and the residue recrystd. from MeOH-EtAc gave 0.31 g. 3-hydroxy-5-pyridineacetic acid (XVI), m. 197° (decomposition). XVI (0.2 g.) heated 15 min. under N at 230° and the residue sublimed at 135/0.05 mm. gave 0.11 g. 3-hydroxy-5-methylpyridine, m. 138.5° (C6H6); picrate m. 189-90°. XII (0.5 g.), 0.1 g. CuSO4.5H2O, and 15 cc. concentrated NH4OH heated 42 h. in a sealed tube at 135 ± 10°, filtered, evaporated in vacuo, and the residue treated with 5 cc. cold H2O gave 105 mg. IV, m. 219-21.5° (decomposition), crystallizing with 0.5 mol H2O. The aqueous filtrate from the crude IV treated with H2S, filtered, evaporated in vacuo, the residue extracted with hot absolute EtOH, the extract evaporated, the residue dissolved in 5 cc. absolute EtOH, the solution diluted with 30 cc. Me2CO, filtered, concentrated to 1/3 the original volume, and the pale orange deposit (0.11 g.) recrystd. from absolute EtOH-C6H6 and H2O gave 23 mg. 2-hydroxy-3-pyridineacetic acid (XVII), m. 240-1° (decomposition). XV (0.16 g.) in 10 cc. 5% aqueous NaOH heated 4.5 h. in an autoclave at 200°, filtered, acidified with concentrated HCl, evaporated, the residue extracted with boiling MeOH, and the extract worked up gave 95 mg. XVII, m. 240-1° (decomposition), red color with FeCl3. IV (0.1 g.) heated 10 min. under N at 225° and the residue sublimed at 170°/10 mm. yielded 56 mg. VI, m. 175°.

IT 74803-15-9P, 1H-Pyrrolo[2,3-b]pyridine, 2,3-diphenyl-
RL: PREP (Preparation)
(preparation of)

RN 74803-15-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-diphenyl- (6CI, 9CI) (CA INDEX NAME)



L4 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1947:25604 CAPLUS
DOCUMENT NUMBER: 41:25604
ORIGINAL REFERENCE NO.: 41:5126f-i,5127a-i,5128a-f
TITLE: Derivatives of 2,6-diaminopyridine
AUTHOR(S): Bernstein, Jack; Stearns, Barbara; Shaw, Elliott; Lott, W. A.
CORPORATE SOURCE: Squibb Inst. for Med. Research, New Brunswick, NJ
SOURCE: Journal of the American Chemical Society (1947), 69,

1151-8
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 41:25604

AB Since 2,6-diaminopyridine (I) showed an appreciable antiparasitic activity when tested against Plasmodium lophurae in ducklings, various derivs. of I have been prepared to determine if further substitution in the mol. would increase the antiparasitic activity of the parent compound I (66 g.) in 300 cc. dioxane, treated dropwise with 23.5 g. AcCl in 50 cc. dioxane (0.5 h.) at 25-30° and stirred 2 addnl. hrs., gives 40% of the 2-Ac derivative (II), m. 156-7°; 2-butyryl derivative m. 152-3°, 25%; 2-salicyloyl derivative (prepared from o-AcOC6H4COCl and purified by precipitation from dilute HCl with dilute NaOH) m. 178-9°, 44%; 2-[phenyl(acetoxy)acetyl] derivative (as HCl salt with 1 mol. H2O) m. 151-3°, 23%. N,N'-Bis(6-amino-2-pyridyl)adipamide m. 228-9°, 72%; N,N'-bis(6-amino-2-pyridyl)sebacamide m. 152-5°, 55%. 1,3-Bis(6-amino-2-pyridyl)urea does not melt, 71%. (CH2CO)2O (30 g.) in 200 cc. dioxane, treated slowly with 33 g. I in 200 cc. dioxane and heated 3 h. on the steam bath, gives 57% N-(6-amino-2-pyridyl)succinamic acid, m. 174-5° (decomposition). I (46 g.) and 222 cc. AcCH2CO2Et, heated 15 min. at 160° and the product in EtOH treated with alc. HCl, give 40% 2,6-bis(acetylacetamido)pyridine-HCl, m. 195-8°; the filtrate yields 10% of the 2-acetylacetamido derivative, m. 146-7°. I (22 g.) and 22.6 g. NCCH2CO2Et, heated 2 h. at 165°, give 85% 2-amino-6-cyanoacetamidopyridine, m. 152-3°. 2-Acetamido-6-carbethoxyacetamidopyridine m. 150-1.5°, 41%. I (282 g.) and 290 g. HOCH2CO2H, fused 15 h. at 120° under reduced pressure, give 35% 2,6-bis(glycolylamino)pyridine, m. 220-1°. I (33 g.) in 200 cc. absolute EtOH containing 6.9 g. Na and 43 g. Et2NCH2CO2Et, refluxed 2 h., give 55% 2,6-bis(diethylaminoacetamido)pyridine, m. 109.5-10.5°. I (22 g.) and 27 g. AcNHCOCl, ground in a mortar and 35 cc. C5H5N added, give 19% 2,6-bis(acetamidoacetamido)pyridine, m. 260-1°. MeC(:NH)NH2.HCl (24.6 g.) in 100 cc. absolute EtOH, added to 22 g. I in 150 cc. absolute EtOH, stirred 3 h., and allowed to stand overnight at room temperature, give 38% N-(6-amino-2-pyridyl)acetamidine-HCl, m. 246-7° (decomposition). I (396 g.) in 8 l. H2O, treated dropwise with 195 g. ClCO2Et (3 h.), gives 76% 2-amino-6-carbethoxyaminopyridine (III), m. 109-12°. I (33 g.) in 500 cc. H2O, 200 cc. N HCl, and 300 g. ice, treated dropwise with 33 g. ClCO2Et, stirred 2 h., 200 cc. N HCl added, and the mixture allowed to stand overnight at 10°, gives 55% 2,6-bis(carbethoxyamino)pyridine, m. 132.5-3.5°, and 12 g. III. III (21.6 g.) in 120 cc. 3 N EtOH-NH3, heated 12 h. at 110°, gives 75% 2-amino-6-ureidopyridine, m. 175-6° (decomposition). I (48 g.) and 48 g. CO(NH2)2, heated 36 h. at 130°, give 49% 2,6-diureidopyridine, does not melt below 300° (purified by extraction with 300 cc. 3% HCl and crystallization of the residue from H2O). I (12 g.) in 1500 cc. C6H6, treated dropwise with 17.9 g. p-EtOC6H4NCO in 75 cc. C6H6, gives 86% 2-(p-ethoxyphenylureido)-6-aminopyridine, m. 168-9°; 2-(2-nitro-4-methoxyphenylureido)-6-aminopyridine m. 208-10°, 73%; reduction over Pt oxide gives 50% of the corresponding 2-(2-amino-4-methylphenylureido) derivative, m. 182-4°. I (154 g.) and 200 g. of the HCl salt of I, heated 12 h. at 190°, give 60% bis(6-amino-2-pyridyl)amine, m. 172-3° (the HCl salt does not melt). 2,6-Dibromopyridine (IV) (38 g.) and 160 cc. 25% aqueous MeNH2, heated 8 h. at 190°, give 59% 2,6-bis(methylamino)pyridine, m. 70-1°; this results in 20% yield from 27.6 g. 2-amino-6-bromopyridine (V) and 110 cc. 25% aqueous MeNH2 on heating 30 h. at 190°. V (80 g.) and 200 cc. EtNH2, heated 36 h. at 170-80°, give 81% 2-amino-6-(diethylamino)pyridine (VI), b4.5 122-3°, m. 34-5° (HCl salt, m. 143-4°). IV (45 g.) and 27.8 g. Et2NH in 100 cc. absolute EtOH, heated 8 h. at 170-80°, give 85%

2-bromo-6-(diethylamino)pyridine (VII), b4 97-9°; VII does not react with NH4OH (d. 0.9) at 170-80° (8 h.); 11 g. VII and 35 cc. 5 N EtOH-NH3, heated 25 h. at 170°, also did not react; 18.8 g. VII in 100 cc. NH4OH (d. 0.9) containing 1 g. CuSO4.5H2O, heated 30 h. at 140-5°, gives 44% VI. IV (35.6 g.) and 100 cc. Et2NH containing 4 cc. 25% CuSO4.5H2O, heated 30 h. at 160°, give 76% 2,6-bis(diethylamino)pyridine, b3 120-2° (HCl salt, m. 120-2°). 2-Amino-6-(3-diethylaminopropylamino)pyridine-HCl m. 65-75°, 53%; 2-acetamido-6-(4-diethylamino-1-methylbutylamino)pyridine m. 106-8° (51%). 2-Acetamido-6-(3-keto-1-methylbutylideneamino)-pyridine, 2,6-AcNHC5H3N(N:CMeCH2Ac), m. 146-7.5°, 40%. 2-Acetamido-6-(2,5-dimethyl-1-pyrryl)pyridine m. 147.5-8.5°, 54%. 2-Methoxy-6,9-dichloroacridine (11.2 g.) in 50 g. PhOH, warmed on the steam bath, treated with 11 g. I, and heated 3 h., gives 61% 2-methoxy-6-chloro-9-(6-amino-2-pyridylamino)acridine, yellow, m. 232-3°. II (30.2 g.), added in small portions to 100 cc. HNO3 (d. 1.5) at -5° to -2° and stirred an addnl. 30 min., gives 65% of the Ac derivative, decompose violently at 193°, of 2-nitramino-6-aminopyridine (VIII), darkens at 240-50° (hydrolysis by refluxing 1 h. with N NaOH); reduction of 15.4 g. VIII in 300 cc. 10% NaOH at 0-2° with 31 g. Zn gives 69% 2-hydrazino-6-aminopyridine, pale yellow, m. 93-4°; warmed 2 h. on the steam bath with AcCH2CO2Et (N atmospheric), there results 44%
1- (6-amino-2-pyridyl)-3-methyl-5-pyrazolone, m. 188-9.5°. 3-Methylpyridine (80 g.), 160 g. PhNMe2, and 144 g. NaNH2, heated 10 h. at 130-50° and 6 h. at 170-200°, give 4% 2,6-diamino-3-methylpyridine, m. 149-50°. 2,6-Dihydroxy-4-methylpyridine (9 g.) and 30 g. PBr3, heated 4.5 h. at 180°, give 36% 2,6-dibromo-4-methylpyridine, m. 74-5°; heated with NH4OH (d. 0.9) 27 h. at 195°, there results 71% 2,6-diamino-4-methylpyridine, m. 87-8°, which on sublimation m. 109-11° but reverts to the lower m.p. on standing. 2,6-Diamino-3-iodopyridine (23.5 g.) in 25 cc. AcOH and 35 cc. Ac2O, heated 1 h. on the steam bath, gives 33% of the di-Ac derivative, m. 210-11°. I (38 g.) in 550 cc. H2O, treated with 93 g. iodine and 93 g. KI in 150 cc. H2O, the mixture stirred 8 h., and allowed to stand overnight at room temperature, gives 36% 2,6-diamino-3,5-diiodopyridine-HCl, m. 160-5°; the free base m. 209-10°.
3-Methoxypyridine (IX) (15.8 g.) in 100 cc. concentrated H2SO4, treated dropwise (with cooling) with 25 cc. HNO3 (d. 1.6) and warmed 6 h. on the steam bath, gives 12.2 g. 3-methoxy-2,6-dinitropyridine (X), m. 114-15°. IX (57 g.), added to 130 cc. concentrated H2SO4 at 5°, the mixture treated with 70 cc. HNO3 (d. 1.6), and heated 1 h. on the steam bath, yields 38 g. 2-nitro-3-methoxypyridine (XI), m. 73-5°; 5 g. XI in 15 cc. concentrated H2SO4, treated with 4 cc. HNO3 (d. 1.6), gives 4.4 g. X. Catalytic reduction (Pt oxide) of 16.8 g. X in 500 cc. AcOH and 250 cc. Ac2O at room temperature (4 h.) gives 60% 3-methoxy-2,6-diacetamidopyridine, m. 173.5-4.5°. 2,3,6-Triaminopyridine-2HCl in 200 cc. H2O and 25 g. Ac2 in 200 cc. H2O, boiled 4 min., yield 98% 2,3-dimethyl-6-aminopyrido[2,3]pyrazine, m. 227-8°; 6-aminopyrido[2,3]pyrazine m. 267°, 62%. 2,3,6-Triaminopyridine oxalate (80 g.) in 150 cc. (CO2Et)2, heated 90 min. at 185°, gives 68% 2,3-dihydroxy-6-aminopyrido[2,3]pyrazine, does not m. below 300°. Addition of 23.8 g. 2,6-diacetamido-3-nitropyridine to 100 g. SnCl2.2H2O in 150 cc. concentrated HCl gives 26% 2-methyl-5-amino-1-imidazo[b]pyridine-HCl; neither the base nor the salt melts. I (55 g.) and 194 g. KCNS in 1 l. 95% AcOH, treated dropwise at -5° to -10° with 26 cc. Br, give 24% 2,5-diaminopyrido[2,3-d]thiazole (XII), m. 138-9°; II likewise gives the 5-Ac derivative of XII, m. 184-5°. I (66 g.) in 2 l. AcOH, treated with 460 g. KCNS in 100 cc. H2O and then at 0-3° with 64 cc. Br, with stirring 1 h. at room temperature, yields 22% 2,6-diaminopyrido[2,3-d,6,5-d']bisthiazole, does not melt below 300°. I (25 g.), 29 g. I.HCl, and 42 g. benzoin,

heated 1 h. at 185°, yield 89% 2,3-diphenyl-6-amino-1-pyrrolo[2,3-b]pyridine, m. 234.5-5.5°. 2-Amino-6-(3-keto-1-methylbutylideneamino)pyridine (16 g.) in 100 cc. 85% H3PO4, warmed 1 h. on the steam bath, gives 84% 2,4-dimethyl-7-amino-1,8-naphthyridine, m. 216-18°; this results in 85% yield from 5 g. I and 5 cc. CH2Ac2 in 25 cc. 85% H3PO4 on warming 30 min. on the steam bath. 2,7-Dihydrazino-4-methyl-1,8-naphthyridine-2HCl-2H2O (23 g.) and 18 g. AcCH2CO2Et in 200 cc. 50% EtOH, heated 5 min. at 70°, give 84% 2,7-bis(3-methyl-5-keto-1-pyrazolyl)-4-methyl-1,8-naphthyridine, m. 260-2°. The most active of these compds. (II, XII, and the di-Ac derivative of I) are only 1/3 as active as quinine as antiparasitic agents for Plasmodium lophurae in ducklings.

IT 55463-74-6P, 1H-Pyrrolo[2,3-b]pyridine, 6-amino-2,3-diphenyl-
RL: PREP (Preparation)
(preparation of)

RN 55463-74-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-amine, 2,3-diphenyl- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 11:28:56 ON 18 DEC 2006)

FILE 'REGISTRY' ENTERED AT 11:29:05 ON 18 DEC 2006
L1 STRUCTURE UPLOADED
L2 5 S L1
L3 302 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:29:39 ON 18 DEC 2006
L4 36 S L3 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	184.42	351.57
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-27.00	-27.00

STN INTERNATIONAL LOGOFF AT 11:30:21 ON 18 DEC 2006